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 Microneedles are arrays of micron-scale projections that penetrate the outer layers of the 
skin, facilitating the transdermal delivery of therapeutics. Using microneedles, molecules that 
cannot passively diffuse across the skin, particularly large, hydrophilic drugs such as biologics, 
can be delivered in a minimally-invasive manner. Microneedles composed of polymers are of 
particular interest for their safety and ability to control release of encapsulated cargo, but these 
microneedles are typically fabricated using time-consuming techniques that are difficult to scale 
up and provide poor control over microneedle design parameters. We have previously 
demonstrated the capability to fabricate microneedles using two novel manufacturing methods, 
the soft lithography technique Particle Replication in Non-wetting Templates (PRINTÒ) and the 
additive manufacturing technique Continuous Liquid Interface Production (CLIP), which have 
the potential to overcome these limitations. Here, we investigate the cargo and microneedle 
parameters important for delivering therapeutics with PRINT and CLIP microneedles.  
 Dissolvable PRINT microneedles were loaded with a range of cargoes, including small 
molecules, proteins, and nanoparticles, with retention of cargo stability throughout the 
microneedle manufacturing process. PRINT microneedles were found to increase the permeation 
of a small molecule dye across murine skin ex vivo compared to passive diffusion. Protein cargo 
was found to permeate murine skin in a molecular weight-dependent manner when applied with
	 iv 
PRINT microneedles, with smaller proteins permeating more extensively. Nanoparticles of a 
range of charges were delivered to murine skin with PRINT microneedles.  
 CLIP was utilized to fabricate drug-encapsulating microneedles composed of polymers 
with swelling, degrading, and dissolving cargo release mechanisms. The small molecule dye 
rhodamine was loaded into and released from CLIP microneedles both in solution and in murine 
skin. CLIP microneedles were fabricated with encapsulated protein cargo, and the stability of the 
protein cargo during the CLIP microneedle manufacturing process was investigated.    
 A method for coating CLIP microneedles with cargo in a spatially-controlled manner 
using CLIP-fabricated coating devices was developed. CLIP microneedles were coated with 
protein cargo, which retained activity throughout the coating process and was rapidly released 
after insertion into skin. Permeation of protein cargo across porcine skin was observed after 
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CHAPTER 1: MICRONEEDLES FOR TRANSDERMAL THERAPEUTIC DELIVERY 
1.1 Transdermal Drug Delivery 
The skin is an advantageous route to administer therapeutics, as it is the largest and most 
accessible organ of the body. Topical delivery, in which a therapeutic is directly administered to 
the skin for the treatment of local cutaneous conditions, avoids exposure to the drug outside of 
the intended site of action. Transdermal delivery involves delivering an agent through the skin, 
most often for systemic treatments. Delivering a drug directly to systemic circulation through the 
skin avoids the degradation and first-pass metabolism associated with oral administration of 
therapeutics, which could, in turn, result in higher bioavailability.1–3 Transdermal delivery also 
has the advantage of controlled therapeutic release, making it easier to maintain a steady level of 
drug in the body with less frequent administration.4,5 Compared to painful hypodermic injections, 
many of which must be administered by trained healthcare professionals, transdermal delivery is 
safe, noninvasive, and patient-accessible.1,2,5  
In traditional transdermal drug delivery, the therapeutic agent is applied to the skin, often 
in the form of an adhesive patch.1 Once applied, the drug must passively diffuse through the skin 
in order to reach systemic circulation and have the intended therapeutic effect. Notable examples 
of drugs delivered via transdermal patches include scopolamine, fentanyl, nicotine, testosterone, 
and estradiol.1,5,6 Around 20 drug formulations are currently marketed for transdermal 
administration, and all of these drugs have similar physicochemical characteristics.7,8 
Transdermally delivered drugs are all small molecules under 500 Da in molecular weight, 




order of milligrams to be effective.1,2,8 The passive transdermal delivery of larger, hydrophilic 
therapeutics remains a challenge, largely due to the barrier properties of the skin. 1,2,5,6 
1.1.1 Skin Structure and Function 
The skin serves as a barrier between the body and the outside world, protecting against 
allergens, pathogens, ultraviolet (UV) light, and chemicals.9 The skin consists of four main 
regions: (1) the stratum corneum, (2) the viable epidermis, (3) the dermis, and (4) the 
subcutaneous tissue (Figure 1.1).9 The outermost region, the stratum corneum, is the main barrier 
layer of the skin. The stratum corneum is 10-20 µm thick and is composed of terminally 
differentiated keratinocytes called corneocytes.3,9,10 These protein-rich corneocytes are arranged 
in a “brick and mortar” structure with a hydrophobic intercellular lipid matrix surrounding the 
corneocytes.3,9–11 Drugs applied to the skin are thought to predominantly transport through the 
stratum corneum via the intercellular route through the lipid matrix, which limits the diffusion of 
large and hydrophilic molecules.9,11,12  
 
Figure 1.1 Structure of the Skin. Skin structure, showing stratum corneum, viable epidermis, 
dermis, and subcutaneous regions. Figure reproduced with permission from reference 13.   
 
The viable epidermis, which begins below the stratum corneum, is a 100-200 µm thick, 
on average, avascular region that contains a number of living cells, the majority of which are 
microneedles is their ability to pierce the skin in a non-invasive and
painless way. Furthermore, microneedles can be integrated into
“lab-on-a-chip” systems, whereby hollowmicroneedles are combined
with either microsensors, micropumps, or both. Such systems can be
used as health monitoring systems for diseases, such as diabetes. The
ultimate goal of “lab-on-a-chip” approaches is to create minimally in-
vasive, fully automated modules for constantly extracting and analyz-
ing biological fluid and directly responding on the analytical results
by the delivery of drugs [1–5]. However, until now there are no
microneedle-based drug delivery systems on the market for (trans)
dermal delivery.
After a short introduction about (trans)dermal drug delivery, this
review describes different production methods for microneedles as
well as factors that influence skin penetration, such as microneedle
geometry and the use of an applicator. Then different (trans)dermal
drug delivery approaches by microneedles are described for solid
and hollow microneedles. Subsequently, the (trans)dermal delivery
of specific drug categories, namely vaccines and therapeutic proteins,
by microneedles is discussed. Finally, perspectives are given for the
linical applic tion of microne dle-based (trans)dermal drug delivery.
2. The skin and its implications for drug delivery
The skin is the largest organ in the human body and is of great im-
portance for the protection of the body against excessive water loss
and to offer a protective barrier against unwanted influences, such
as pathogens. The skin owes its rotective function to its efficient
physical barrier, the stratum corneum, which is 15–20 μm thick and
is indispensible for a proper barrier function as it complicates foreign
compounds, including drugs, to penetrate the skin [6,7]. The viable
epidermis is located below the stratum corneum and has a thickness
of 130–180 μm. Below the epidermis lies the dermis is, which is about
2000 μm thick and contains nerves, blood vessels, nociceptors, lymph
vessels, hair follicles and sweat glands [8–10], s depicted in Fig. 1.
Many drugs are delivered into the body by using conventional hy-
podermic needles and met l lancets for, e.g., subcutane us and
intramuscular injections, whereby the needles are used to pierce
through the skin in order to reach the target site of injection. However,
these procedures cause pain and carry the risk of transmitting various
biohazardous pathogens [10–12]. The skin, however, has a great po-
tential for non- or minimally invasive drug delivery. First of all, the
skin has a large surface area for drug application and the (trans)dermal
route bypasses the first-pass effect of the liver. Besides, steady blood
concentrations of a pharmacon can be reached by the transdermal
route, thereby avoiding fluctuations of the drug concentration in the
blood, associated toxicity and inefficacy. Furthermore, swallowing
problems and drug absorption and stability problems in the gastroin-
testinal tract can be circumvented [9,13–17]. Also, because of the large
number of immune cells, the skin offers a great potential for vaccina-
tion [10–12]. Altogether, drug delivery via the skin has multiple bene-
fits over both the oral route and conventional injections. However, the
dense structure of the stratum corneum and the limited number of
hair follicles and sebaceous glands complicates the delivery of thera-
peutic doses via the skin. Therefore, several methods have been devel-
oped for (trans)dermal drug delivery, such as chemical and lipid
enhancers, and electric fields for iontophoresis [6,14–17]. About 40
(trans)dermal products (20 drug molecules) are on the market, how-
ever, they are all low-molecular-weight drugs with a high potency
[16,18,19]. This illustrates that it is difficult to overcome the skin bar-
rier. As it is even more difficult to deliver high-molecular-weight
drugs, such as proteins, polypeptides, oligonucleotides, and DNA,
and even larger entities such as vaccines, novel methods have been
developed to deliver such drugs via the skin. Among these methods
are various microneedle approaches, which are the focus of our re-
view. Microneedles are very promising for the (trans)dermal delivery
of high-molecular-weight drugs because they enabling large mole-
cules to pass the stratum corneum via micropores.
3. Microneedle production, geometry, and application technology
3.1. Production of microneedles
Numerous types of microneedles composed of various materials
have been used for the (trans)dermal delivery of a broad range of
compounds in a painless manner, a selection of which is shown in
Fig. 2. The first produced microneedles for drug delivery were made
from siliconwafers by photolithography and deep reactive ion etching
[13,20,21]. The used microfabrication technologies were initially de-
veloped for the production of integrated circuits and turned out to
be very suitable for the highly-reproduciblemass production ofmicro-
needles. Furthermore, these technologies enable the integration of,
e.g., microsensors, micropumps, electrical circuits, and microneedles
into one device [1,13,21–26]. Another benefit of silicon microneedles
is that they are usuallymuch sharper than polymeric andmetalmicro-
needles [27]. However, the production process for silicon micronee-
dles requires expensive micro-fabrication processes and clean room
processing. Another drawback of silicon needles is that they may
break and stay behind in the skin due to the fragile nature of silicon
[28–35].
Microneedles produced from silicon wafers have been developed
with multiple geometries and can be divided into two major groups:
in-plane and out-of-plane microneedles, as shown in Fig. 3. In-plane
microneedles are formed in parallel with the machined surface of
the silicon wafer, enabling the production of needles with various
lengths over a large range. In-plane production techniques are
state-of-the-art techniques, including surface micromachining and a
variety of etching methods. Furthermore, they offer flexibility regard-
ing needle design and shape, and are beneficial for the integration of
microneedles with biosensors and micropumps [1,22,40–43]. Out-of-
plane microneedles are formed perpendicular to the silicon wafer and
are more easily produced in arrays than in-plane microneedles. Fur-




Microneedle Micron-scaled needle-like structure with a
maximum length of 1 mma
Dermal drug delivery Delivery of drugs into the skin with the skin
as the target (local delivery)
Transdermal drug delivery Delivery of drugs through the skin, thus where
the skin is not the target (systemic delivery)
a Longer needles have been used (up to 3 mm), which are however not microneedles
in the strictest sense
Fig. 1. Representation of t e ski microanatomy.




keratinocytes.4,9,11 Langerhans cells, the major antigen-presenting cells of the skin, melanocytes, 
which produce melanin, and Merkel cells, which are involved in the sensation of touch, are also 
present in the epidermis.9,10 The dermis lies below the epidermis, separated by a glycoprotein 
basement membrane termed the dermal-epidermal junction.4,11 The dermis, which is 1-2 mm 
thick, is mainly comprised of the fibrous proteins collagen and elastin, which provide support 
and elasticity, respectively, within a matrix of mucopolysaccharides.4,9 There are a limited 
number of cells within the dermis, including fibroblasts, macrophages, mast cells, melanocytes, 
and dermal dendritic cells.4,9,11 The dermis contains blood vessels, which extend within 200 µm 
of the skin’s surface, as well as lymph vessels, nerve endings, hair follicles, and sebaceous and 
sweat glands.4,9,11 Once most therapeutics reach the dermis, they encounter little resistance to 
permeation and can be rapidly absorbed into systemic circulation.4,9 Below the dermis lies the 
subcutaneous tissue, or hypodermis, which is mainly comprised of fat cells connected by 
collagen and elastin along with blood vessels and nerves.9,11 
1.1.2 Skin Permeation 
The permeation of a molecule across the skin can be modeled by Fickian diffusion laws 
shown in Equation 1.1, where the rate of permeation (J) of the molecule across the skin is 
proportional to the partition coefficient of the molecule between the stratum corneum and the 
vehicle (Ksc/veh), the diffusion coefficient of the molecule in the stratum corneum (D), and the 
concentration of the molecule in the vehicle (Cveh) and is inversely proportional to the length of 
the diffusion path (h).3,4,9,14 
 ! = #$%/'()*+'(),  (1.1) 
In order to increase the permeation of a drug across the stratum corneum, the partition 




diffusion path must be decreased. However, the diffusion path length, or the thickness of the 
stratum corneum, is not easily altered, while the concentration of the drug in the vehicle is 
limited by the solubility of the drug.3,4 Therefore, the most promising choices for enhancing the 
permeation of a drug across the skin are to increase the partitioning of the molecule into the 
stratum corneum or to increase the diffusion of the molecule within the stratum corneum.4,15 
Chemical permeation enhancers have been utilized to passively increase small molecule 
drug permeation through the skin by reversibly altering the structure of the stratum corneum.1,14 
These permeation enhancers, including alcohols, fatty acids, and water, increase the partitioning 
of drugs into or the diffusion of drugs within the stratum corneum by disrupting or fluidizing the 
intercellular lipid bilayers or by increasing the hydration of the stratum corneum.1,6,9,14 However, 
many of these permeation enhancers have poor permeation across the stratum corneum 
themselves, which limits their efficacy in enhancing the permeation of other drugs.16 Chemical 
permeation enhancers, especially potent ones, have also been shown to cause skin irritation, as 
their disruption of the stratum corneum allows them to diffuse into the deeper layers of the viable 
epidermis where they can cause cytotoxicity.16,17 
Physical methods of increasing permeation of molecules across the stratum corneum have 
also been utilized as an alternative to the passive permeation enhancement provided by chemical 
enhancers. Examples of physical permeation enhancement methods include iontophoresis, 
electroporation, thermal ablation, jet injection, and sonophoresis, which utilize forces including 
electric currents, heat, and pressure to permeabilize the stratum corneum and drive molecules 
across the skin.1,5,14 These physical permeation enhancement methods more effectively disrupt 
the stratum corneum barrier than chemical methods and have increased the ability to deliver high 




methods require the use of costly specialized devices and are often used in a clinical setting.1 The 
physical permeation method that has garnered the most attention is microneedle technology, 
which utilizes micron-scale needles to pierce the outermost layers of the skin, enhancing the 
permeation of therapeutics to the deeper layers of the skin in a straightforward manner.4  
1.2 Microneedles 
Microneedles are arrays of microprojections, typically between 25 and 2000 µm in 
height, that penetrate the stratum corneum and viable epidermis to deliver therapeutic cargo to 
the skin in a minimally-invasive manner for both local and systemic applications.4 Microneedles 
create micron-sized channels in the skin, facilitating the delivery of cargo of a range of sizes, 
from small molecules to biologics and nano- and microparticles.1 Once delivered to the skin 
using microneedles, these cargoes have the potential to reach systemic circulation through the 
blood vessels or lymphatic drainage in the dermis.18,19 Additionally, microneedles can be used 
for intradermal delivery of cargo within the skin, which is particularly promising for vaccine 
applications. The skin contains a high number of immune cells, including the antigen-presenting 
Langerhans cells in the epidermis and dermal dendritic cells in the dermis, that can be targeted to 
induce an immune response.4,20,21 Microneedle vaccines have been shown to produce immune 
responses that are equal or dose-sparing compared to other traditional routes of administration, 
including intramuscular and subcutaneous injections.22–25 
Microneedles are generally regarded as a patient-friendly approach to therapeutic 
administration. The small size of the microneedles means they can better avoid the nerve endings 
within the dermis than larger hypodermic needles, causing minimal or no pain upon 
application.26–28 As microneedles are more similar to patches or bandages than traditional 




hypodermic needles.27,29 Microneedles can also be self-administered either by hand or with an 
applicator, making them more accessible than forms of hypodermic injections that must be 
administered by trained healthcare professionals.18,30  
1.2.1 Microneedle Classes 
Microneedles can be divided into four classes based on their method of delivering 
therapeutics: (1) solid, (2) hollow, (3) coated, and (4) drug-encapsulating (Figure 1.2).4,13,26,31 
Solid microneedles are applied to the skin, then removed. The area where the microneedles were 
applied is then covered with a therapeutic formulation, which diffuses through the channels 
created by the microneedles.4,26 Hollow microneedles contain open bores through the center of 
the needles, through which liquid formulations can be pumped.4,26 Coated microneedles have a 
drug formulation coated on the surface of the microneedles. Upon insertion into skin, the coating 
dissolves, releasing the drug in the skin.4,26 Drug-encapsulating microneedles are composed of 
dissolvable, degradable, or swellable materials with the therapeutic encapsulated within the 
microneedle matrix. When inserted into skin, the drug is released from the microneedle in a 





Figure 1.2 Microneedle Classes. Application and drug release method of solid, coated, hollow, 
and drug-encapsulating microneedles. Figure adapted from reference 12.   
 
 Solid microneedles were the first type of microneedles developed and are intended to 
increase the permeability of topically-applied substances.32 The topically-applied drug can be 
formulated to release in a controlled manner over an extended period of time.13,18 Solid 
microneedles are not limited in the quantity of therapeutic they can be used to deliver, but their 
reliance on passive diffusion results in poor control over dosing.13 Additionally, the two-step 
application process required with solid microneedles has the potential to interfere with patient 
compliance.4 
 Hollow microneedles are most similar to traditional hypodermic needles and function in 
the same manner, where a drug solution is allowed to passively diffuse or is pumped through the 
needles. The rate and amount of drug administered to the skin can be more easily controlled than 





























microneedles.12,13,25 However, the hollow microneedles are more complex than other 
microneedle classes, especially in cases where a pumping mechanism is involved, which could 
limit their accessibility to patients.13,25,33 
 Coated microneedles are coated with a dried layer of therapeutic which is released, 
usually within seconds to minutes, when inserted into skin.31,34 Coated microneedles are simple 
to use with a one-step application process and have more control over dosing than solid 
microneedles.13 Therapeutic cargo has been shown to maintain stability on coated microneedles 
for extended periods of time when stored at room temperature, eliminating the need for cold 
chain storage of a liquid drug formulation.24,35,36 The major limitation of therapeutic delivery 
with coated microneedles is the limited quantity of therapeutic that can be coated on the 
microneedles, typically less than 1 mg per patch, making coated microneedles only suitable for 
delivering potent molecules such as vaccines.25,34  
 Drug-encapsulating microneedles contain the drug within the microneedle, which is then 
released through dissolution, degradation, or swelling of the microneedles when inserted in skin. 
These microneedles are often composed of biocompatible polymeric materials which are left in 
the skin in the case of dissolvable or degradable needles, eliminating the need for disposal of 
hazardous sharps waste.13,37,38 The application process for drug-encapsulating microneedles is 
simple, and dosing can be more controlled than with some other microneedle classes.13 
Controlled release of encapsulated therapeutics is achievable with drug-encapsulating 
microneedles, with release times of minutes to days or months depending on the microneedle 
material selection.31,38,39 However, drug-encapsulating microneedles are more limited in the 




encapsulation within the microneedle has the potential to alter the mechanical strength of the 
needle and the stability of encapsulated cargo.13,25 
1.2.2 Microneedle Manufacturing 
Although the concept of microneedles for drug delivery has existed since at least 1971, 
the capability to manufacture microneedles did not exist until the 1990s with the emergence of 
the fabrication techniques utilized in the microelectronics industry.40–42 The first microneedles 
for drug delivery were fabricated from silicon using lithography and reactive ion etching.32 Since 
this time, microneedles have been fabricated from a variety of materials, including silicon, metal, 
and polymers, using a wide range of techniques (Figure 1.3). 
 
 
Figure 1.3 Silicon, Metal, and Polymer Microneedles. (A) Silicon microneedle produced using 
reactive ion etching. (B) Stainless steel microneedles fabricated using laser cutting. (C) 
Carboxymethylcellulose microneedles fabricated using micromolding. Images reproduced with 
permission from references 32, 43, and 38, respectively.  
 
1.2.2.1 Silicon and Metal Microneedle Fabrication 
 Silicon and metal are commonly used to make solid and hollow microneedles, which can 
be further modified with a therapeutic coating to produce coated microneedles. Silicon 
microneedles can be directly fabricated using processes including reactive ion etching and wet 
etching.4,32,44–46 Both reactive ion etching and wet etching microneedle fabrication begin with the 
patterning of an etch mask on a silicon wafer using lithographic techniques.4,42 The silicon 
material is then etched using a plasma of reactive ions in the case of reactive ion etching or a 
liquid chemical such as potassium hydroxide in the case of wet etching to produce 
(F igure 2). Moreover , a ll bu t a few percent of the micro-
needles remained fu lly in tact . On those very few which
broke, only the top 5-10 µm was damaged. Microneedle
ar rays could a lso be removed without difficu lty or ad-
dit iona l damage, as well as reinser ted in to skin mult iple
t imes.
To quant ita t ively assess the ability of microneedles to
increase t ransdermal t ranspor t , we measured ca lcein
permeability of human epidermis with and without in-
ser ted microneedle arrays. Calcein crosses skin very poorly
under normal circumstances and therefore represents an
especia lly difficu lt compound to deliver . As expected,
passive permeability of ca lcein across una ltered skin was
very low, indicat ing that the epidermis samples were intact
(F igure 3). Moreover , in cont rol exper iments where bare
pieces of silicon with no microneedles etched in to them
were pressed aga inst the skin , skin permeability was not
a ffe ted (da ta not shown).
Inser t ion of microneedles in to skin was capable of
dramat ica lly increasing permeability to ca lcein (Figure 3).
When microneedles were inser ted and left embedded in the
skin , ca lcein permeability was increased by more than
1,000-fold. Inser t ion of microneedles for 10 s, followed by
their removal, yielded an a lmost 10000-fold increase.
F ina lly, inser t ion of a microneedle ar ray for 1 h , followed
by ts removal, increased skin permeability by about 25000-
fold. Permeabilit ies for skin with microneedles inser ted
and then removed are h igher than for skin with micro-
needles remain ing embedded probably because the micro-
needles themselve or the silicon plate su port ing the array
may block access to the microscopic holes crea ted in the
skin . Light microscopy showed tha t the holes which
remained in the skin after microneedles were removed were
approximately 1 µm in size (da ta not shown).
Increased skin permeability appeared to occur rapidly
after microneedle inser t ion and to be mainta ined for hours
in vit ro. Skin permeability measurements were made once
every hour . Elevated permeability was always seen during
the fir st hour after microneedle inser t ion and remained a t
approximately the same level for as much as 5 h (da ta not
shown); longer exper iments were not performed. Although
reversibility was not seen , and would not be expected in
vit ro, holes crea ted by microneedles in vivo are likely to
resea l, a lthough the kinet ics of resea ling are present ly
unknown.
To supplement in vit ro exper iments which showed tha t
skin permeability can be significan t ly increased by micro-
needles, preliminary resu lt s were obta ined from studies
with human volunteers, for which informed consent and
IRB approva l have been secured. They indica ted tha t
Figure 1sScanning electron micrographs of microneedles made by the
reactive ion etching technique. (a) A section of a 20 by 20 array of
microneedles. (b) Close-upviewof amicroneedle tip. Microneedlesareuniform
insizeandsharpat their tips, which is important for easy insertion toadesired
depth in skin.
Figure2sMicroneedl tips insertedacrossepidermis. Anarrayofmicroneedles
was inserted into thestratumcorneumsideof humanepidermis. Theunderside
of theepidermis is shown, indicating that themicroneedles penetratedacross
the tissue and that the tips were not damaged. Arrows indicate some of the
microneedle tips.
Figure 3sPermeability of human skin treated with different microneedle
protocols in vitro. Increases of 3 to 4 orders of magnitud were ob erved for
microneedles (1) inserted and left in skin, (2) inserted for 10 s and then
removed, and (3) inserted for 1 h and then removed. Such large increases in
skin permeability have the potential to significantly increase the number and
types of drugs which can be delivered across the skin. Each data point
represents the average of 7 to 9 experiments. Standard deviation bars are
shown.
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microneedles.32,44 Metal microneedles composed of materials including stainless steel and 
titanium can also be fabricated using the wet etch process or by using laser cutting to fabricate 
microneedles out of metal sheets.4,34,47,48 
 Silicon and metal microneedles have several limitations due to the fabrication techniques 
used to make them and due to the properties of the materials. The etching techniques used to 
generate silicon and metal microneedles are fairly complex, require specialized training, and can 
be time consuming.12,13,49 Additionally, only microneedles of limited geometries can be produced 
using these techniques. The fabrication of microneedles using etching techniques is generally 
limited to microneedles less than 500 µm in height, and the aspect ratio of the needles cannot be 
easily controlled.4,32,44,50 Wet etching also necessitates large interneedle spacing, which can limit 
the microneedle density on the array.4,44 As silicon and metal are not biodegradable, and silicon 
is not biocompatible, adverse effects could occur if microneedles of these materials were to 
fragment in the skin.4,26,37,38  
1.2.2.2 Polymer Microneedle Fabrication 
 As a result of the limitations associated with the fabrication and use of silicon and metal 
microneedles, polymer microneedles have become increasingly popular. A range of polymeric 
materials, including poly(lactide-co-glycolide) (PLGA),39,51,52 poly(vinyl pyrrolidone) (PVP),53–
55 poly(methylvinylether-co-maleic anhydride) (PMVE/MA),56,57 poly(acrylic acid) (PAA),58 
carboxymethylcellulose (CMC),38,59,60 hyaluronic acid,61–63 silk fibronin,64–66 and others, have 
been utilized to fabricate microneedles. These materials are biocompatible and dissolve or 
degrade after insertion into skin, minimizing the risk of adverse immunological reactions 




 A number of fabrication techniques have been utilized to manufacture polymeric 
microneedles, including drawing lithography,67 droplet-born air blowing,68 and electrodrawing.69 
However, the most common polymer microneedle fabrication technique is micromolding (Figure 
1.4). In the micromolding process, a microneedle master is fabricated from metal or silicon, 
typically using one of the previously described fabrication techniques for metal and silicon 
microneedles or an alternative approach such as multidirectional UV lithography.39,51,70,71 An 
inverse mold of the microneedle master is then created using a non-wetting polymer, frequently 
poly(dimethylsiloxane) (PDMS).38,51,53,60 Finally, the PDMS mold is filled with the desired 
polymeric microneedle material and any cargo of interest, often by applying vacuum and 
centrifugal force.38,51,53,60 After the mold is filled and the microneedle has solidified, the mold is 
removed, leaving the final microneedle patch.  
 
 
Figure 1.4 Microneedle Micromolding Process. An inverse microneedle mold is fabricated 
from a microneedle master. The mold is then filled with the microneedle material, which is 
solidified and removed from the mold to produce the microneedle patch.  
 
 Micromolding is a useful method for producing polymeric microneedles, but the process 
has a few limitations. The fabrication of microneedles using this technique is often time 
consuming, with hours to days necessary for filling the mold alone and additional time required 
to generate the microneedle masters and PDMS molds.38,66 The techniques used to fill the 






manner that would be difficult to scale up in an industrial setting.22,72 If polymer microneedles 
are to be successfully commercialized for vaccine and therapeutic delivery applications, 
improved manufacturing techniques are necessary. 
1.3 Particle Replication in Non-Wetting Templates (PRINT) Microneedles 
To overcome some of the limitations associated with polymeric microneedle 
manufacturing, the technology Particle Replication in Non-wetting Templates (PRINT) has been 
applied to microneedle fabrication. PRINT was originally developed as a top-down nano- and 
microparticle fabrication technique, in which non-wetting perfluoropolyether (PFPE) molds are 
used to precisely shape monodisperse particles with a range of compositions, sizes, shapes, and 
surface functionalities.73–75 PRINT has been utilized to fabricate dissolvable square pyramidal 
PVP microneedles, with fabrication times of less than 5 minutes per patch (Figure 1.5).72  
 
 
Figure 1.5 PVP PRINT Microneedles. Brightfield images of PRINT microneedles loaded with 
the small molecule dye rhodamine. Scale bars measure 200 µm in (A) and 1 cm in (B,C). Figure 







A schematic of the PRINT microneedle fabrication process is shown in Figure 1.6. A pre-
microneedle solution containing PVP and any cargo of interest is drop-cast to form solid pre-
microneedle films. The pre-microneedle film is then placed on a PFPE microneedle mold, which 
is passed through a heated laminator to melt the film and fill the mold. The filled mold is then 
placed on flexible, water-soluble backing layer composed of a poly(vinyl pyrrolidone) / 
poly(vinyl acetate) blend and once again passed through the heated laminator. The mold is 
removed from the microneedles, leaving a fully water-soluble microneedle patch. The PRINT 
microneedle fabrication process is highly scalable and can be used to make microneedle patches 
of any size quickly and efficiently.72 PRINT microneedles have been shown to effectively deliver 
an encapsulated small molecule drug surrogate to skin ex vivo, suggesting they hold promise for 
delivering therapeutic cargo transdermally.72  
 
 
Figure 1.6 PRINT Microneedle Fabrication Process. A solid pre-microneedle film (red) 
composed of PVP is mated to a microneedle mold (green), then passed through a heated nip to 
fill the mold. A flexible backing layer (yellow) is then mated to the filled microneedle mold and 
passed through the heated nip. The microneedle mold is removed, leaving a microneedle array on 






1.4 Additive Manufacturing for the Fabrication of Microneedles 
Additive manufacturing, or three-dimensional (3D) printing, has emerged in recent years 
as a microneedle manufacturing technology with the potential to overcome some of the 
limitations associated with traditional methods of making microneedles. Most current 
microneedle manufacturing techniques require long lead times and involve many time-
consuming fabrication steps, particularly for making molded polymeric microneedles.38,66 
Additionally, these fabrication methods are only able to produce microneedles of limited 
geometries.4,32,44,50,56 As microneedle geometry, including factors such as needle height,76–79 
needle density,76,80 shape,81,82 and tip radius,83,84 has been demonstrated to influence the efficacy 
of microneedles in delivering therapeutics, the ability to rapidly alter microneedle geometry in a 
controlled manner would be valuable in designing the optimal microneedle array for specific 
therapeutic applications.   
 Using additive manufacturing, computationally designed microneedles can be directly 
fabricated in a single step, with minimal lead time and without the geometric limitations imposed 
by other manufacturing techniques.50 In additive manufacturing, the desired object is 
computationally designed using 3D modeling software to generate a computer-aided design 
(CAD) file of the object.85 This CAD file is then sliced into cross-sections, which are fabricated 
one layer at a time to produce the object.85 Additive manufacturing includes such techniques as 
selective laser sintering, fused deposition modeling, and stereolithography.86 Stereolithography 
(SLA), which uses photopolymerization to create objects layer-by-layer from a liquid resin, is 
the most commonly utilized additive manufacturing method for the production of microneedles 




 Microstereolithography has been used to manufacture microneedles composed of the 
biodegradable photopolymerizable polymer poly(propylene fumarate) (PPF) with a layer-by-
layer fabrication process (Figure 1.7A).87,88 Using a digital micromirror device (DMD), UV light 
was projected in the shape of the appropriate microneedle cross-sectional layer into a vat of 
photopolymerizable liquid resin, which contained the polymers PPF and diethylfumarate, a 
photoinitiator, and the chemotherapy drug dacarbazine.87 Once one layer had cured, the stage 
which it was adhered to was moved further down into the vat of resin, and the process was 
repeated for the next layer.87 Microneedles fabricated in this manner were 1000 µm tall with a 20 
µm layer thickness and had a fabrication time of around 1 hour per patch.87 Dacarbazine 
encapsulated within the PPF microneedles was found to slowly release over the course of 35 
days in solution.87 
 
Figure 1.7 Microneedles Fabricated with Additive Manufacturing. (A) PPF microneedles 
produced using microstereolithography. (B) Ormocer microneedles produced using two-photon 
polymerization. Images reproduced with permission from references 87 and 90, respectively.  
 
 Another stereolithography technique used to fabricate microneedles is two-photon 
polymerization (2PP) (Figure 1.7B). In 2PP, an ultrashort-pulsed laser is traced in 3 dimensions 
through a photopolymerizable liquid resin.89,91 The laser excites the photoinitiator in the resin 





photopolymerization of the resin.89,91 With 2PP, very small volumes of resin can be selectively 
photopolymerized to produce high resolution features of less than 100 nm, although there is a 
trade-off of longer production times for higher resolution features.50 The 2PP process has been 
utilized to fabricate microneedles of a range of geometries and compositions including Ormocer, 
a photopolymerizable organically modified ceramic material, and poly(ethylene glycol) 
dimethacrylate.92,93 However, the 2PP microneedle fabrication process is slow, especially for 
high resolution microneedles, which has limited its utility for direct microneedle fabrication.90 
Instead, 2PP microneedles are often utilized as microneedle masters, which are used to 
manufacture polymeric microneedles with further micromolding steps.50,90,93,94 
1.4.1 Continuous Liquid Interface Production (CLIP) 
 While microstereolithography and 2PP have been used to successfully fabricate 
microneedles, the layer-by-layer nature of these techniques results in slow fabrication times, with 
a trade-off between microneedle resolution and manufacturing efficiency.50 In traditional SLA, 
each layer of the object is cured, then must be repositioned before the next layer is fabricated. 
While the use of thinner layers results in higher resolution of the object, the number of time-
consuming repositioning steps also increases, leading to longer production times. Continuous 
Liquid Interface Production (CLIP) is a continuous, rather than layer-by-layer, additive 
manufacturing technique that can overcome some of the limitations associated with traditional 
SLA microneedle production.95,96 The CLIP process works by shining UV light through an 
oxygen-permeable window into a vat of photopolymerizable liquid resin to selectively cure it. 
Above the window, an oxygen-inhibited “dead zone” of unpolymerized liquid resin is 




traditional SLA (Figure 1.8).95 Using CLIP, high resolution structures can be fabricated with no 
trade-off between resolution and fabrication time (Figure 1.9).95,97 
 
 
Figure 1.8 Differences between Stereolithography and CLIP. In traditional stereolithography, 
each layer is cured, then separated and repositioned. CLIP eliminates the need for separation and 
repositioning due to the presence of the oxygen-inhibited dead zone, allowing for continuous 
production. Figure reproduced from reference 96.   
  
Figure 1.9 Layer Thickness vs Fabrication Time Trade-Off. In traditional layer-by-layer 
additive manufacturing techniques, increasing resolution by decreasing the layer thickness leads 
to longer fabrication times. With CLIP, there is no trade-off between resolution and fabrication 




The CLIP process has previously been applied to the fabrication of polymeric 
microneedles.96 An overview of the CLIP microneedle manufacturing process is shown in Figure 
1.10. Microneedles are computationally designed using modeling software to generate a CAD 
file of the microneedle patch. The microneedle CAD file is then sliced into cross-sections, which 
are projected in succession using UV light off a digital light projection (DLP) chip through a UV 
and oxygen-permeable window into a pool of photopolymerizable liquid resin. Above the 
oxygen-inhibited dead zone, the area where UV light hits the resin is selectively polymerized on 
the build elevator, which moves upward as cross-sections are projected for continuous 
production of the microneedle patch. Using CLIP, high resolution microneedles of a range of 
geometries can be fabricated in a matter of minutes (Figure 1.11). This ability to rapidly alter 
microneedle design parameters could be a valuable tool in fabricating microneedles for drug 
delivery applications.  
 
 
Figure 1.10 CLIP Microneedle Fabrication Process. Microneedles CAD files are 
computationally sliced into cross-sections, which are then projected using UV light into a pool of 
photopolymerizable liquid resin, selectively curing it. An oxygen-permeable window below the 
resin vat results in a dead zone with no polymerization, which enables continuous production as 




















Figure 1.11 CLIP Microneedle Geometries. Trimethylolpropane triacrylate (TMPTA) 
microneedles produced using CLIP. Microneedle (A) aspect ratio, (B,C) spacing, (D,F) shape, 
and (E) height can be controlled. Scale bars measure 500 µm. Figure reproduced from reference 
96.   
 
1.5 Thesis Overview 
Microneedles show promise for enhancing the transdermal delivery of a range of 
therapeutics, but current microneedle manufacturing processes are time-consuming, difficult to 
scale up, and have limited control over microneedle design parameters. In this work, we utilize 
two novel microneedle manufacturing techniques, PRINT and CLIP, to fabricate polymeric 
microneedles for drug delivery applications. In Chapter 2, the ability to fabricate dissolvable 
PRINT microneedles loaded with a range of model and therapeutic cargoes, including small 
molecules, proteins, and nanoparticles, is demonstrated, and the transdermal permeation of these 
microneedle-delivered cargoes is assessed ex vivo. In Chapter 3, we demonstrate the ability to 
fabricate CLIP microneedles composed of a library of drug-releasing materials and investigate 
their utility for delivering encapsulated small molecule and protein cargo. In Chapter 4, a method 
for coating CLIP microneedles with cargo is established, and the delivery of protein cargo using 
coated CLIP microneedles is investigated ex vivo. A summary and recommendations for future 
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CHAPTER 2: CARGO DELIVERY WITH DISSOLVABLE PRINT MICRONEEDLES 
2.1 Introduction 
 The transdermal delivery of therapeutics is a minimally-invasive alternative route of 
administration for drugs that are typically given with hypodermic needle-based injections. While 
small, moderately lipophilic molecules with molecular weights under 500 Da are able to diffuse 
through the skin, larger molecules are unable to cross the stratum corneum barrier through 
passive diffusion.1,2 Microneedles help to bypass the barrier function of the skin, facilitating the 
delivery of therapeutics for both local and systemic applications. Microneedles have been 
utilized to enhance the permeation of a range of model and therapeutic cargoes through the skin, 
including small molecules, biologics, and nanoparticles.  
 Microneedles have been shown to increase the rate and extent of permeation of small 
molecules across skin compared to passive diffusion alone, particularly for hydrophilic and 
highly lipophilic small molecules and those with molecular weights greater than 500 Da.3–6 
Using microneedles, small molecules can be delivered to the skin for local applications, such as 
lidocaine delivery for local anesthesia7–9 and photosensitizer delivery for photodynamic 
therapy.10–12 Microneedles have also been developed for the delivery of small molecules with 
systemic applications, including sumatriptan for the treatment of migranes,13,14 methotrexate for 
the treatment of rheumatoid arthritis,15,16 and naltrexone for the treatment of opioid and alcohol 
addiction.17,18 To enter systemic circulation, therapeutics must reach the dermal blood supply that 
begins 200 µm deep within the skin, a feat achievable with the use of microneedles.2
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Delivery of biologic therapeutics, including proteins and nucleic acids, is a promising 
application of microneedles, as these therapeutics are currently administered through more 
invasive parenteral injections.19,20 A number of protein therapeutics have been delivered with 
microneedles, including insulin,21–23 parathyroid hormone,24,25 human growth hormone,26,27 and 
erythropoietin.28,29 Perhaps the most widely investigated microneedle application is vaccine 
delivery. The skin contains a number of antigen-presenting cells, including Langerhans cells in 
the epidermis and dermal dendritic cells in the dermis.2,30,31 When vaccines are administered 
intradermally using microneedles, potent immune responses are generated which are dose-
sparing compared to other forms of administration.2,32 Microneedles have been used to deliver 
vaccines for influenza,33–36 anthrax,37,38 and human papilloma virus,39 among others.  
Particle-based formulations have also been investigated for delivery with microneedles. 
Using microneedles, drug-loaded micro- and nanoparticles can be delivered to the skin, where 
they serve as a depot for sustained therapeutic release.40,41 The delivery of particles is of 
particular interest for microneedle-based vaccine applications, as antigen-loaded micro- and 
nanoparticles can more effectively target the numerous antigen-presenting cells present in the 
skin compared to soluble antigen.42–44 Physiochemical characteristics of particles, including their 
size, composition, and charge, have been shown to influence the efficacy of particle-based 
vaccines, but the role of particle characteristics in microneedle-based vaccination has not been 
extensively investigated.42,45,46 
We have previously demonstrated the ability to fabricate dissolvable microneedles using 
the soft lithography technique Particle Replication in Non-wetting Templates (PRINT).47 The 
microneedle matrix, which consists of the water-soluble polymer poly(vinyl pyrrolidone) (PVP) 
and any cargo of interest, is drop-cast to form solid pre-microneedle films, which are then 
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molded into microneedles by heating the film to fill a non-wetting perfluoropolyether (PFPE) 
microneedle mold. A flexible, water-soluble poly(vinyl pyrrolidone) / poly(vinyl acetate) 
backing layer is then utilized to remove the needles from the mold, producing a completely 
water-soluble microneedle patch. PRINT microneedles have been shown to successfully 
penetrate skin ex vivo, where they rapidly dissolved and released the encapsulated small 
molecule dye rhodamine.47 
In this chapter, we demonstrate the ability to fabricate PRINT microneedles loaded with 
small molecules, proteins, and nanoparticles of a range of sizes and charges. The stability of 
encapsulated protein cargo was analyzed throughout the PRINT microneedle fabrication process. 
Permeation kinetics of each of the microneedle cargoes through ex vivo murine skin were 
investigated using Franz diffusion testing, and distribution profiles of the cargoes within skin 
were assessed.  
2.2 Materials and Methods 
2.2.1 Materials 
 Poly(ethylene glycol) diacrylate (Mn = 700) (PEG700DA), 2-aminoethyl methacrylate 
hydrochloride (AEM), diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide (TPO), poly(vinyl 
pyrrolidone) (PVP) (Mw = 10,000), triethyl citrate, sucrose, ovalbumin from chicken egg white 
(OVA), butyrylcholinesterase from equine serum (BuChE), and phosphate buffered saline (PBS) 
(pH = 7.4) were obtained from Sigma Aldrich. Dimethylformamide (DMF), trimethylamine 
(TEA), pyridine, acetic anhydride, and borate buffer (pH = 9.5) were obtained from Fisher 
Scientific. Poly(vinyl alcohol) (Mw = 2,000) (PVOH) and rhodamine B base were obtained from 
Acros Organics. AlexaFluor 488 C5 maleimide, AlexaFluor 488 ovalbumin conjugate, 
AlexaFluor 488 N-hydroxysuccinimide (NHS) ester, and gel electrophoresis supplies including 
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NativePage 4-16 % Bis-Tris gels, NativePage sample buffer, NativePage running buffer kit, and 
Coomassie R-250 were obtained from Thermo Fisher Scientific. Methoxy-PEG(5k)-succinimidyl 
carboxy methyl ester (mPEG5k-SCM) was obtained from Creative PEGWorks. Luvitec VA64 
was obtained from BASF. Aldolase from rabbit muscle was obtained from Worthington 
Biochemical. Aldolase Activity Colorimetric Assay Kit was obtained from Biovision. 
Paraformaldehyde solution, 4% in PBS, was obtained from Affymetrix USB. Frozen-Fix was 
obtained from Cancer Diagnostics. Tissue-Tek optimum cutting temperature compound was 
obtained from Sakura Finetek. 80 x 80 x 320 nm PRINT molds were obtained from Liquidia 
Technologies. Tetraethylene glycol monoacrylate (HP4A) was synthesized in house as previously 
described.48 
2.2.2 PRINT Hydrogel Particle Fabrication and Characterization 
 80x320 nm PRINT hydrogel particles were fabricated as previously described.49,50 A pre-
particle solution of 3.5 wt% (% weight per weight) solids in isopropanol, of which the solids 
were composed of 68 wt% HP4A, 10 wt% PEG700DA, 20 wt% AEM, 1 wt% TPO, and 1 wt% 
AlexaFluor 488 C5 maleimide, was prepared. Using a custom roll-to-roll PRINT particle 
fabrication system, a film of pre-particle solution was drawn with a #3 Mayer rod onto a corona-
treated poly(ethylene terephthalate) (PET) sheet at a speed of 12 feet/minute. After drawing the 
film, solvent was evaporated from the PET sheet with the use of heat guns. The dried film on 
PET was laminated to the 80x320 nm mold at a pressure of 80 pounds per square inch (psi) for 
mold filling, followed by delamination. The particles were cured by exposing the filled mold to 
UV-LED (Phoseon, l = 395 nm, 3 SCFM N2). The mold was then laminated to a harvesting 
sheet consisting of a PVOH film on PET at 140 °C and 80 psi. The mold was manually removed 
from the harvesting sheet, and particles were harvested by dissolving the PVOH film with a bead 
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of water. Particles were filtered through a 2 µm filter (Agilent) to remove large particulates. The 
particles were then washed to remove excess PVOH by centrifuging at 21,000 g for 15 minutes 
using an Eppendorf Centrifuge 5417R, followed by removal of the supernatant and resuspension 
of the particles in sterile water. This washing process to remove PVOH was repeated 3 times.  
 A portion of the 80x320 nm hydrogel particles were PEGylated by resuspending 5 mg of 
particles in 1 mL DMF. Next, 100 µL of TEA was added to the particle suspension and mixed at 
1400 rpm on a shaker plate (Eppendorf) for 10 minutes at room temperature, followed by 
addition of 140 µL of a 100 mg/ml mPEG5k-SCM in DMF solution to the particle suspension, 
which was mixed overnight. Particles were then washed via centrifugation as previously 
described, first in DMF for 3 washes, then in water for 4 washes followed by resuspension in 
water.  
 Following PEGylation, a portion of the particles were further modified by acetylation. 
Particles were resuspended in DMF at 5 mg/mL, then mixed with 50 µL of pyridine and 70 µL 
of acetic anhydride for 30 minutes on a shaker plate (Eppendorf, 1400 rpm) at room temperature. 
The particles were then washed once in DMF, once in borate buffer (pH 9.5), and 3 times in 
water.  
 Particle concentration was determined using thermogravimetric analysis (TGA) (TA 
Instruments Q5000). 20 µL of the particle solution in water was added to a tared aluminum 
sample pan, which was heated at 30 °C/minute to 130 °C, held at 130 °C for 10 minutes, then 
cooled at 30 °C/minute to 30 °C and held at 30 °C for 2 minutes. 20 µL of the water supernatant 
following particle centrifugation was run through the same method to determine residual PVOH 
mass, and the concentration of the supernatant was subtracted from the concentration of the 
particle solution to determine final particle concentration.  
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 For imaging, particles were dried on a silicon wafer and coated with 1.5 nm of gold-
palladium alloy using a Cressington 108 auto sputter coater. The particles were then visualized 
using scanning electron microscopy (SEM) with a Hitachi S-4700 SEM. Particle size and zeta 
potential were measured using a Zetasizer Nano ZS (Malvern Instruments).  
2.2.3 Microneedle Fabrication and Characterization 
2.2.3.1 Rhodamine Microneedle Fabrication 
Microneedles were fabricated using PRINT as previously described.47 A pre-microneedle 
solution containing 15 wt% solids in water, of which the solids were composed of 1 wt% 
rhodamine B base and 99 wt% PVP, was prepared. The pre-microneedle solution was drop-cast 
onto a sheet of PET and allowed to dry at room temperature for 24 to 48 hours to form pre-
microneedle films. The films were placed on a perfluoropolyether (PFPE) microneedle mold and 
covered with a plastic sheet, then passed through a heated nip at 105 °C and 50 psi to fill the 
microneedle molds. The plastic sheet was removed, and a microneedle backing layer composed 
of 2 wt% triethyl citrate in Luvitec VA64 was placed over the mold, then covered with a plastic 
sheet. The mold and backing layer were passed through a heated nip at 105 °C and 50 psi, 
followed by removal of the microneedles from the mold.  
2.2.3.2 Protein Microneedle Fabrication 
 AlexaFluor 488 OVA conjugate was purchased pretagged and was utilized as received. 
Aldolase and equine BuChE proteins were tagged with AlexaFluor 488 NHS ester prior to 
microneedle fabrication. Solutions of each protein were prepared in PBS at 10 mg/mL, while a 
solution of AlexaFluor 488 NHS ester was prepared in DMF at 10 mg/mL. The AlexaFluor 488 
NHS ester solution was mixed with the protein solution at a 3-fold molar excess of dye to 
protein, then incubated for 1 hour at room temperature. The protein solutions were then filtered 
 33 
using Millipore Amicon Ultra centrifugal filters with a molecular weight cut off of 30 kDa for 
aldolase and 100 kDa for BuChE to separate unreacted dye. Following centrifugation, protein 
solutions were dialyzed overnight in PBS at room temperature using 20 kDa Slide-A-Lyzer 
cassettes (Thermo Scientific). Protein concentrations were determined using a NanoDrop 2000 
(Thermo Scientific).  
Pre-microneedle solutions containing AlexaFluor 488-labeled OVA, aldolase, and 
BuChE were prepared at 15 wt% solids in water, with 20 wt% protein and 80 wt% PVP solids. 
Microneedles were fabricated as described above for the rhodamine microneedles, with the 
exception that the nip used for lamination was heated to 77-82 °C to preserve protein activity.  
2.2.3.3 Nanoparticle Microneedle Fabrication  
 Prior to encapsulation in microneedles, unmodified, PEGylated, and acetylated 80x320 
nm hydrogel particles were resuspended in methanol. Pre-microneedle solutions were prepared at 
40 wt% solids in methanol, with 5 wt% particles and 95 wt% PVP solids. Microneedles were 
fabricated as described above for the rhodamine microneedles.   
2.2.3.4 Microneedle Characterization 
 Microneedle patches were imaged with environmental scanning electron microscopy 
(ESEM) (FEI Quanta 200) in low vacuum mode to visualize morphology and with fluorescence 
confocal microscopy (Zeiss LSM 700) to visualize fluorescent cargo distribution.  
2.2.4 Protein Stability Assessment 
 The stability of OVA throughout the microneedle fabrication process was assessed using 
non-denaturing polyacrylamide gel electrophoresis (NativePAGE). OVA-loaded pre-
microneedle solution, films, and microneedle patches were prepared as described above, then 
dissolved in PBS. NativePAGE was performed using an XCell SureLock Mini-Cell (Thermo 
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Fisher Scientific) and NativePAGE Novex 4-16% Bis-Tris gels according to the manufacturer’s 
instructions. 5-15 µg of sample was loaded per well, with unprocessed OVA and NativeMark 
Unstained Protein Standard utilized as controls. The gel was run at 150 V for 120 minutes, then 
stained with Coomassie R-250 to visualize bands 
Aldolase stability was assessed through enzyme activity measurements using an Aldolase 
Activity Colorimetric Assay Kit. Aldolase pre-microneedle solution and films were prepared as 
described above. Films were passed through a heated laminator at 77-82 °C and 50 psi to mimic 
microneedle fabrication conditions. Unprocessed and processed films were dissolved in PBS, 
and activity of aldolase in the pre-microneedle solution, unprocessed films, and process films 
was measured per the manufacturer’s instructions. Briefly, 50 µL of the aldolase samples were 
added to 50 µL of a reaction mix containing fructose-1,6-bisphosphate. Aldolase converts the 
fructose-1,6-bisphosphate to glyceraldehyde-3-phosphate and dihydroxyacetone phosphate, 
which produce a colored probe with absorbance at 450 nm through further reactions. Absorbance 
of the samples at 450 nm was correlated to aldolase activity using a standard curve.  
BuChE stability was assessed using a VITROS CHE cholinesterase activity assay (Ortho 
Clinical Diagnostics). BuChE pre-microneedle solution and films were prepared as described 
above, and films were processed as previously described for aldolase. Unprocessed and 
processed films were dissolved in PBS, and the activity of BuChE in the samples was measured 
according to the manufacturer’s instructions. Samples were applied to slides coated with 
potassium ferricyanide and butyrylthiocholine iodide. BuChE reacts with the butyrylthiocholine 
to produce thiocholine, which then goes on to react with the potassium ferricyanide to produce 
potassium ferrocyanide. The loss of color associated with potassium ferrocyanide production, 
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which is proportional to the BuChE activity, was assessed with reflectance spectrophotometry at 
400 nm using a VITROS DT60 chemistry system (Ortho Clinical Diagnostics).  
2.2.5 Franz Diffusion Cell Permeation Assessment 
2.2.5.1 Rhodamine Pre-Microneedle Solution Permeation  
Permeation kinetics of rhodamine in the pre-microneedle solution were assessed using 
excised nude murine skin with the permission of the UNC Institutional Animal Care and Use 
Committee (IACUC). Skin was excised from the back of nude mice (nu/nu), flash frozen, and 
stored at -20 °C until testing. Skin was thawed in Eppendorf tubes in a 37 °C water bath, then the 
fat was gently removed from the underside of the skin. The skin was placed between the donor 
chamber and PBS-filled receptor chamber of a jacketed 15 mm, 5 mL Franz diffusion cell 
(PermeGear). A 12.5 µL aliquot of a pre-microneedle solution containing 15 wt% solids in 
water, of which the solids were composed of 99 wt% PVP and 1wt% rhodamine B base, was 
applied to the murine skin through the receptor compartment. The Franz cell was placed in a 
water bath at 37 °C with continuous stirring of the receptor compartment at 200 rpm. At time 
points over the course of 24 hours, 400 µL samples were removed from the receptor chamber 
and replaced with an equal volume of fresh PBS. Concentration of rhodamine in the receptor 
chamber fluid was measured via fluorescence using a plate reader (SpectraMax M5, Molecular 
Devices), with excitation at 544 nm and emission at 590 nm. Fluorescence was correlated to 
rhodamine mass using a standard curve, then expressed as percent of the original rhodamine dose 
applied at each time point.  
2.2.5.2 Rhodamine, Protein, and Nanoparticle Microneedle Permeation 
 Cargo mass in rhodamine, protein, and nanoparticle-loaded microneedle patches was 
determined using fluorescence imaging with an in vivo imaging system (IVIS) Spectrum (Caliper 
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Life Sciences). Microneedle patches containing rhodamine were imaged with excitation at 535 
nm and emission at 580 nm, while patches containing AlexaFluor 488-labeled proteins and 
nanoparticles were imaged with excitation at 465 nm and emission at 520 nm. A series of pre-
microneedle films containing known amounts of each of the fluorescent cargoes were prepared 
as a standard curve and imaged in the same manner. Cargo loading in each microneedle patch 
was determined by correlating the radiant efficiency of the patch to that of the pre-microneedle 
film standard curve.  
Microneedle patches containing rhodamine, the proteins OVA, aldolase, and BuChE, and 
unmodified, PEGylated, and acetylated nanoparticles were applied to excised murine skin using 
force of thumb for 10 seconds, then allowed to sit in the skin for 8 minutes. Next, 100 µL of 
water was applied to back of the microneedle patch to dissolve the backing layer, which was then 
wiped away using medical wipes. The process of water application and wiping the skin was 
repeated 3 times to clean the skin. The microneedle-treated skin was placed between the donor 
and receptor chambers of the Franz diffusion cell, and cargo permeation was measured in the 
same manner as described for the rhodamine pre-microneedle solution Franz diffusion cell 
experiment. For AlexaFluor 488-labeled protein and nanoparticle permeation quantification, an 
excitation of 495 nm and emission of 525 nm was utilized.  
 In the rhodamine-loaded microneedle permeation experiments, the mass of rhodamine 
removed from the surface of the skin via wiping was quantified and subtracted from the mass of 
rhodamine in the microneedle patch. The medical wipes used to wipe the skin were allowed to 
dry, then placed in PBS on a shaker for 1 hour to extract rhodamine from the wipes. The mass of 
rhodamine in the PBS was determined via fluorescence using a plate reader (SpectraMax M5, 
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Molecular Devices) with excitation at 544 nm and emission at 590 nm. For the standard curve, 
known quantities of rhodamine were applied to wipes and extracted in the same manner.  
2.2.6 Cargo Release in Skin 
 To assess diffusion of cargo into the skin in absence of microneedles, pre-microneedle 
films containing AlexaFluor 488-labeled OVA, aldolase, BuChE, and unmodified nanoparticles 
were applied to excised murine skin using force of thumb for 10 seconds, then left on the skin for 
8 minutes. Water was applied to dissolve the film, then the skin was wiped clean with medical 
wipes. The skin was fixed in a 2 % paraformaldehyde in PBS solution for 2 hours at 4 °C, then 
stored in a 15 % sucrose in PBS solution at 4 °C until analysis. 
 Upon termination of Franz diffusion cell experiments for all cargoes at 24 hours, the pre-
microneedle and microneedle-treated skin was fixed as described above for the pre-microneedle 
film-treated skin. Pre-microneedle solution, pre-microneedle film, and microneedle-treated skin 
samples were embedded in optimum cutting temperature compound and cryosectioned into 12 
µm sections using a Leica Cryostat at -25 °C. The skin sections were fixed in Frozen-Fix for 10 
seconds, then imaged using differential interference contrast (DIC) and fluorescence microscopy 
(Olympus BX61 Upright Wide Field Microscope).  
2.2.7 Statistical Analysis 
 Statistical analysis was performed using GraphPad Prism 5 software. Unpaired t-tests 
were utilized to compared two groups, while one-way analysis of variance (ANOVA) was used 





2.3 Results and Discussion 
2.3.1 Small Molecule Permeation with Microneedles 
 Rhodamine B base, a fluorescent dye, was utilized to assess the ability of PRINT 
microneedles to enhance the transdermal delivery of a small molecule cargo. Typically, 
compounds with molecular weights of less than 500 Da and moderate lipophilicity, with log P 
values between 1 and 3, are able to passively diffuse through the skin.1,2,51,52 Rhodamine B base 
has a molecular weight of 442 Da, below the cutoff for passive transdermal delivery. However, 
its log P value of 4.23 falls outside the optimal lipophilicity range, suggesting microneedles may 
enhance the permeation of rhodamine across skin. Dissolvable microneedles composed of the 
water-soluble polymer PVP and rhodamine were fabricated using PRINT. These microneedles 
were square pyramidal shaped, approximately 360 µm in height and 200 µm wide at the base 
with 200 µm spacing between needles. Rhodamine-loaded microneedles showed consistent 
morphology, with fluorescent cargo distribution throughout the needles (Figure 2.1).  
 
 
Figure 2.1 Rhodamine-Loaded PRINT Microneedles. ESEM (A,B) and fluorescence confocal 
(C) images of microneedle patches containing rhodamine. Scale bars measure 200 µm.  
 
 The permeation of rhodamine across skin when applied in the form of a liquid solution 
and in microneedles was assessed using a Franz diffusion cell. A diagram of a static Franz 
diffusion cell is shown in Figure 2.2. The device, which is made from inert glass, consists of a 
donor chamber and a receptor chamber separated by a membrane. The receptor chamber is filled 
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with a fluid appropriate for solubilizing the compound being studied, then the compound of 
interest is applied to the membrane through the donor chamber. The device is maintained at 37 
°C by running water through the jacket surrounding the receptor chamber. Permeation of the 
compound through the membrane is measured by removing samples of the receptor chamber 
fluid over time and assessing the concentration of the compound in the fluid through methods 
such as chromatography, enzyme-linked immunosorbent assay, or fluorescence.53,54 Excised skin 
from nude mice was utilized as the membrane for permeation experiments due to its availability 
and potential for translation into in vivo studies using the same species.  
 
 
Figure 2.2 Franz Diffusion Cell Device. Schematic of static Franz diffusion cell used for 
permeation measurements. Figure reproduced from reference 53.   
 
 To assess permeation kinetics, equivalent doses of rhodamine pre-microneedle solution 
and rhodamine-loaded microneedles were applied to full thickness murine skin. The pre-
microneedle solution was applied to the skin through the donor chamber of the Franz diffusion 
cell, while the microneedles were applied to the skin with force of thumb and left in the skin for 
8 minutes to dissolve. The backing layer of the patch was then dissolved with water, and the skin 
was placed between the donor and receptor chambers of the Franz cell. Concentrations of 
rhodamine in the receptor chamber fluid were measured over the course of 24 hours using 
fluorescence.  
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 Permeation kinetics of rhodamine across murine skin when administered in solution and 
in dissolvable microneedles are shown in Figure 2.3. The rhodamine solution showed limited, 
linear diffusion across the skin, reaching a maximum of 7 % of the administered dose permeating 
at 24 hours. The microneedles showed more extensive permeation, with 18 % of the 
administered dose permeating the full skin thickness at 24 hours, with a slowing of permeation 
observed after 12 hours. These results demonstrate that PRINT microneedles are able to increase 
the rate and extent of permeation of small molecule cargo compared to passive diffusion alone.   
 
 
Figure 2.3 Ex Vivo Permeation Kinetics of Rhodamine. Permeation kinetics of rhodamine 
across murine skin when delivered in a solution and in dissolvable microneedles (n = 3).   
 
At the termination of the Franz diffusion cell experiment at 24 hours, the murine skin was 
fixed, sectioned, and imaged with differential interference contrast (DIC) and fluorescence 
microscopy to visualize distribution of the rhodamine dye within the skin. Rhodamine was 
observed to be distributed throughout the full thickness of the murine skin with a high 
fluorescent signal when administered in a solution, while rhodamine administered from PRINT 
microneedles had a lower fluorescent signal in the skin. (Figure 2.4A,B). In contrast, murine skin 
that had not been treated with rhodamine solution or microneedles showed no fluorescent 




















rhodamine signal (Figure 2.4C). The high fluorescent rhodamine signal seen in the solution-
treated skin suggests there is still rhodamine remaining in the skin that has yet to passively 
diffuse at 24 hours, which is supported by the linear permeation kinetics with no slowing of 
permeation observed during the Franz diffusion cell experiment. The lower fluorescent signal 
observed in the microneedle-treated skin supports the more extensive permeation seen in the 
Franz diffusion cell experiment compared to solution-treated skin. 
 
 
Figure 2.4 Ex Vivo Rhodamine Release. DIC and fluorescence microscopy overlay images of 
skin after treatment with (A) rhodamine pre-microneedle solution and (B) rhodamine 
microneedles. Untreated murine skin is shown in (C). Scale bars measure 40 µm.  
 
2.3.2 Protein Permeation with Microneedles 
 Three proteins with a range of molecular weights and charges were chosen for 
incorporation in PRINT microneedles: ovalbumin (OVA), aldolase, and butyrylcholinesterase 
(BuChE). OVA, a protein present in chicken egg white, is commonly used as a model antigen in 
immunology research. OVA has a molecular weight of 45 kDa and isoelectric point of 4.5, 
making it negatively charged at neutral pH.55 Aldolase is an enzyme present in all animal and 
plant tissue and in most microorganisms that catalyzes the conversion of D-fructore-1,6-
bisphosphate to dihydroxyacetone phosphate and D-glyceraldehyde-3-phosphate, a reaction 
important for glycolysis.55 Here, aldolase was utilized as a model enzyme and was chosen for its 
intermediate molecular weight of 160 kDa and positive charge at neutral pH due to its isoelectric 
point of 8.5.55 BuChE, an endogenous enzyme with a molecular weight of 338 kDa and 
isoelectric point of 4.2-4.9, has therapeutic function as a systemic organophosphate nerve agent 
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scavenger.56–58 Equine BuChE, which shares 90 % homology with human BuChE, was utilized 
here due to its low cost and availability.57  
 Microneedles containing OVA, aldolase, and BuChE proteins were fabricated using 
PRINT in the same manner as the rhodamine-loaded microneedles. However, a lower 
temperature of 77-82 °C was utilized for mold-filling and lamination steps in order to protect the 
stability of the proteins during the fabrication process. Microneedles loaded with each of the 
proteins, which were labeled with AlexaFluor 488 prior to incorporation into the microneedles, 
showed similar needle morphology and homogenous distribution of the proteins throughout the 
needles (Figure 2.5).  
 
 
Figure 2.5 OVA, Aldolase, and BuChE-Loaded PRINT Microneedles. ESEM (top) and 
confocal fluorescence (bottom) images of microneedles loaded with AlexaFluor 488-labeled 
OVA, aldolase, and BuChE. Scale bars measure 200 µm.   
 
 Maintenance of the stability of encapsulated proteins during the PRINT microneedle 
fabrication process is essential for therapeutic efficacy. During the mold-filling step of PRINT 
microneedle fabrication, proteins are exposed elevated temperatures of 77-82 °C for a short 
period of time, and exposure to temperatures this high has the potential to alter the structure and 
OVA Aldolase BuChE
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function of proteins.20,59 The stability of encapsulated proteins was assessed throughout the 
PRINT microneedle fabrication process. For OVA, nondenaturing polyacrylamide gel 
electrophoresis was utilized to assess the structure of the protein during microneedle fabrication. 
Unprocessed OVA in the pre-microneedle solution, OVA that has been dried into a pre-
microneedle film, and OVA that had been processed into microneedles show similar migration of 
bands on the gel, suggesting the structure of OVA is not altered during the microneedle 
fabrication process (Figure 2.6A). The activity of the enzymatic proteins aldolase and BuChE 
was measured to assess their function during the microneedle fabrication process. Compared to 
the activity of the enzymes in pre-microneedle solution, no significant difference was observed 
in activity after drying into pre-microneedle films or after exposure to microneedle processing 
conditions for either aldolase or BuChE (Figure 2.6B). The retention of structure seen with OVA 
and retention of activity observed for aldolase and BuChE demonstrate that protein stability can 
be maintained during PRINT microneedle fabrication.   
 
 
Figure 2.6 Protein Stability during PRINT Microneedle Fabrication. (A) Nondenaturing gel 
of OVA during PRINT microneedle fabrication, showing (1) ladder, (2) pre-microneedle 
solution, (3) pre-microneedle film, and (4) microneedles. (B) Activity of aldolase and BuChE 
during microneedle fabrication, expressed as percent of pre-microneedle solution activity 








































 The ability of the OVA, aldolase, and BuChE proteins to passively diffuse through skin 
was assessed by applying solid pre-microneedle films containing each of the fluorescently-
labeled proteins to murine skin with force of thumb, mimicking microneedle application 
conditions. The films were left on the skin, then dissolved with water and wiped away. After film 
application, the skin was fixed, sectioned, and imaged with DIC and fluorescence microscopy to 
visualize diffusion of the proteins. No fluorescent signal was observed in the murine skin 
following protein-loaded film application, confirming these large molecular weight proteins are 
not able to passively diffuse (Figure 2.7).  
 
 
Figure 2.7 Ex Vivo Diffusion from Protein-Loaded Pre-Microneedle Films. DIC and 
fluorescence microscopy overlays of murine skin treated with (A) OVA, (B) aldolase, and (C) 
BuChE-loaded microneedles. Scale bars measure 40 µm.  
 
The permeation kinetics of OVA, aldolase, and BuChE when administered via PRINT 
microneedles were assessed using murine skin as a membrane with Franz diffusion testing. 
Microneedles loaded with each of the fluorescently-labeled proteins were applied to murine skin 
in the same manner as the rhodamine-loaded microneedles, and permeation of the proteins 
through the murine skin was measured over the course of 24 hours using fluorescence. The 
permeation kinetics of the proteins were found to differ based on molecular weight (Figure 2.8). 
The 45 kDa OVA protein permeated the most extensively, with 18 % of the applied dose 
permeating the full thickness of the skin at 24 hours. In contrast, the larger 160 kDa aldolase and 
338 kDa BuChE proteins showing more limited permeation, with 10 % and 2 % of the applied 
dose permeating the skin at 24 hours, respectively. These results suggest protein charge is not the 
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main determinant of skin permeation, as the two negatively charged proteins with similar 
isoelectric points, OVA and BuChE, showed vastly different permeation profiles.  
 
 
Figure 2.8 Ex Vivo Permeation Kinetics of OVA, Aldolase, and BuChE. Permeation kinetics 
of OVA, aldolase, and BuChE across murine skin when administered with microneedles (n = 3).  
 
 The microneedle-treated skin was fixed, sectioned, and imaged following termination of 
the Franz diffusion cell experiment to visualize distribution of the protein cargo in the murine 
skin. The cargo once again showed a molecular weight-dependent difference in distribution 
(Figure 2.9). The smallest protein, OVA, was distributed through the full thickness of the skin, 
while the larger aldolase was more concentrated in epidermis, upper dermis, and around sites of 
penetration. The largest BuChE protein showed little diffusion away from sites of penetration, 
supporting the limited permeation observed in the Franz diffusion experiment.  
 
 
























Figure 2.9 Ex Vivo Protein Release from Microneedles. DIC and fluorescence overlay images 
of murine skin after treatment with microneedles containing (A) OVA, (B) aldolase, and (C) 
BuChE. Scale bars measure 40 µm.  
 
OVA and aldolase were found to permeate the full thickness of murine skin, with the 
proteins visually observed in the dermal layers of the skin 24 hours after microneedle 
application. The ability of these proteins to permeate to the dermal layers of the skin suggests 
they may have potential to reach the dermal capillaries and systemic circulation.2,60 The limited 
permeation observed with BuChE is likely due to its larger size, which will hinder diffusion 
away from sites of penetration after the protein is deposited in the skin using microneedles. 
Longer microneedles, which insert deeper in the skin and closer to the dermal capillary bed, may 
be necessary for increased permeation and potential systemic uptake of high molecular weight 
proteins.2,60 
2.3.3 Nanoparticle Permeation with Microneedles 
 To investigate the ability of PRINT microneedles to deliver nanoparticles, 80x320nm 
hydrogel PRINT particles were utilized. These rod-shaped particles are composed of the UV-
curable monomer tetraethylene monoacrylate (HP4A) with PEG700DA as a crosslinker and 2-
aminoethyl methacrylate (AEM) as a functional handle to allow for post-fabrication 
modifications. An SEM image of the monodisperse 80x320 nm hydrogel PRINT particles is 





Figure 2.10 80x320 nm Hydrogel PRINT Particles. SEM image of unmodified 80x320 nm 
hydrogel PRINT particles. Scale bar measures 1 µm.  
 
 After fabrication, hydrogel PRINT particles can be further functionalized by conjugation 
through the amino handle of the AEM in the particles to produce particles of different charges. 
Poly(ethylene glycol) (PEG), commonly used as a stealth coating to extend particle circulation 
and increase particle hydrophilicity, was conjugated to the hydrogel particles.49 While the 
unmodified particles have a positive charge, with a zeta potential of +33.6 mV, conjugation of 
PEG to the particles resulted in a more neutral zeta potential of +24.3 mV (Table 2.1). The 
PEGylated particles were further modified with acetic anhydride to quench the unreacted amines 
on the particles. These acetylated particles had a negative charge, with a zeta potential of             
-16.4 mV (Table 2.1). Size and polydispersity index as determined by dynamic light scattering 
are shown in Table 2.1 for all 80x320 nm hydrogel particles.  
Table 2.1 Characterization of 80x320 nm hydrogel PRINT particles.  
  
 Unmodified, PEGylated, and acetylated hydrogel PRINT nanoparticles containing 
AlexaFluor 488 dye were utilized to fabricate PRINT microneedles. Due to swelling of the 
Particle Diameter	(nm) Polydispersity	Index Zeta	Potential	 (mV)
Unmodified 272.8	± 7.2 0.083	± 0.017 +33.6	± 2.2
PEGylated 551.5	± 6.6 0.314	± 0.014 +24.3	± 0.6
Acetylated 489.3	± 4.4 0.307	± 0.003 -16.4	± 0.5
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hydrogel particles in water, methanol was utilized as the solvent to make the pre-microneedle 
solution of 5 wt% particles and 95 wt% PVP. Other than the pre-microneedle solution solvent, 
hydrogel particle-loaded microneedles were fabricated in the same manner as the rhodamine-
loaded microneedles. Particles of all surface charges were successfully loaded into PRINT 
microneedles, with no significant difference in particle loading among the different particle types 
(Table 2.2). The unmodified particles showed the most homogenous loading in the microneedles, 
while PEGylated and acetylated particles had more uneven distribution (Figure 2.11). We 
hypothesize that the presence of PEG conjugated to the surface of the PEGylated and acetylated 
particles may contribute to the uneven distribution of these particles in the microneedles.  




Figure 2.11 Particle-Loaded PRINT Microneedles. Fluorescence confocal images of PRINT 
microneedles containing AlexaFluor 488-labeled (A) unmodified, (B) PEGylated, and (C) 
acetylated 80x320 nm hydrogel PRINT particles. Scale bars measure 200 µm.  
 
 The ability of PRINT microneedles to deliver nanoparticles through murine skin was 
assessed. Microneedles containing fluorescent unmodified, PEGylated, and acetylated 80x320 
nm hydrogel PRINT particles were applied to murine skin as previously described. The 







microneedles through the murine skin was measured over 24 hours using fluorescence. Limited 
permeation of the particles through the full thickness skin was observed, with less than 4 % of 
the original dose of particles permeating in 24 hours for all particles (Figure 2.12). This limited 
permeation of particles through the skin is expected, as their large size will hinder diffusion after 
insertion into the skin with microneedles. The charge of the particle did not appear to affect the 
permeation kinetics, which were highly variable.  
 
 
Figure 2.12 Ex Vivo Permeation Kinetics of 80x320 nm Particles. Permeation kinetics of 
unmodified, PEGylated, and acetylated 80x320 nm hydrogel particles through murine skin when 
administered using PRINT microneedles (n = 3).  
 
 After termination of the Franz diffusion cell experiment, the microneedle-treated skin 
was fixed, sectioned, and imaged with DIC and fluorescence microscopy to assess distribution of 
the nanoparticles within the skin. To confirm the inability of nanoparticles to passively diffuse 
through the skin, a pre-microneedle film containing fluorescent unmodified 80x320 nm hydrogel 
particles was applied to murine skin, dissolved with water, and wiped away to mimic 
microneedle application. The skin was fixed, sectioned, and imaged to assess particle diffusion. 
No diffusion of particles through the skin was observed when applied in the form of a pre-
























microneedle film, suggesting these particles do not passively diffuse (Figure 2.13A). Skin treated 
with unmodified, PEGylated, and acetylated particles in microneedles showed concentration of 
the particles around sites of microneedle application, with limited diffusion away from 
penetration sites regardless of charge (Figure 2.13B-D). These particles were able to reach the 
epidermis and upper dermal layers of the skin, which are areas rich in antigen presenting cells, 




Figure 2.13 Ex Vivo Particle Release. Murine skin after treatment with (A) unmodified 80x320 
nm particle pre-microneedle film, (B) unmodified 80x320 nm particle microneedles, (C) 
PEGylated 80x320 nm particle microneedles, and (D) acetylated 80x320 nm particle 
microneedles. Scale bars measure 40 µm.  
 
2.4 Conclusions 
 In this work, we have demonstrated the ability to fabricate dissolvable PRINT 
microneedles loaded with a range of cargoes, including a small molecule dye, proteins, and 
80x320 nm nanoparticles. PRINT microneedles were shown to enhance the permeation of the 
small molecule dye rhodamine through ex vivo murine skin compared to passive diffusion. 
Model and therapeutic proteins of a range of molecular weights and charges were found to retain 




successfully delivered to the skin using PRINT microneedles. Molecular weight was shown to 
influence permeation of proteins through murine skin when applied using microneedles, with 
smaller proteins exhibiting more extensive permeation. 80x320 nm nanoparticles were 
successfully delivered to skin using PRINT microneedles, but the charge of the particle did not 
seem to affect permeation. PRINT microneedles show promise for delivering a range of 
therapeutic cargoes, but an alternative microneedle geometry might be necessary to increase 
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CHAPTER 3: ENCAPSULATED CARGO DELIVERY WITH CLIP MICRONEEDLES1 
3.1 Introduction 
 Traditional microneedle fabrication often involves manufacturing solid silicon or metal 
microneedles through methods such as silicon etching and laser cutting.1 These microneedles are 
then directly used to deliver therapeutics or are used as masters to generate polymeric 
microneedles through further micromolding steps.1 The process to fabricate either solid silicon or 
metal microneedles or molded polymeric microneedles is often lengthy, with lead times of weeks 
to months necessary to generate the solid microneedles and several additional hours to days 
required to produce molded polymeric microneedle patches.2–4 Additionally, most traditional 
microneedle manufacturing techniques can only produce microneedles of limited geometries, 
which can hinder the ability to alter microneedle characteristics such as height, spacing, and 
shape.5,6 
 As previously demonstrated, the additive manufacturing technique Continuous Liquid 
Interface Production (CLIP) can be used to rapidly fabricate microneedles in a single step with a 
high degree of control over microneedle design.7 Microneedle patches are computationally 
designed, then fabricated using CLIP in a matter of minutes.7 This quick fabrication time and
																																																						
1 Parts of this work were previously published in: Johnson AR, Caudill CL, Tumbleston JR, 
Bloomquist CJ, Moga KA, Ermoshkin A, et al. Single-Step Fabrication of Computationally 





 ability to alter microneedle design characteristics, including needle height, spacing, geometry, 
and composition, provides an unprecedented capability to rapidly investigate microneedle 
parameters important for specific drug delivery applications.  
 The CLIP process can be applied to the manufacture of polymeric microneedles of each 
of the 4 microneedle classes: (1) solid, (2) hollow, (3) coated, and (4) drug-encapsulating. Drug-
encapsulating microneedles, which release encapsulated therapeutics through swelling, 
degradation, or dissolution of the microneedle matrix upon insertion into skin, have several 
advantages over the other microneedle classes. Drug encapsulating microneedles are composed 
of materials, such as polymers and sugars, that dissolve or degrade in the skin, eliminating the 
need for disposal of biohazardous waste.3 Microneedles made of metal or silicon can break in the 
skin, which could cause adverse immunologic reactions, while the biocompatible materials used 
to make drug-encapsulating microneedles pose less of a risk.1 One of the most promising 
advantages drug-encapsulating microneedles have over the other microneedle classes is the 
ability to control drug release rates based on the microneedle composition.1   
 Polymeric materials with a variety of cargo release mechanisms, namely swelling, 
degradation, and dissolution, have been used for the controlled delivery of therapeutics.8,9 
Swelling materials, often referred to as hydrogels, are crosslinked networks of hydrophilic 
polymers, such as poly(ethylene glycol), poly(vinyl alcohol), and poly(N-isopropylacrylamide), 
that swell when in contact with water or other aqueous fluids.10,11 Cargo release occurs through 
diffusion out of the crosslinked matrix and can be controlled by altering the crosslink density of 
the hydrogel.10,11 Biodegradable polymers contain bonds that can be hydrolyzed or enzymatically 
degraded, leading to either bulk or surface erosion of the polymer over a sustained period of 
time.12,13 Examples of biodegradable polymers used for drug delivery include poly(lactide), 
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poly(lactide-co-glycolide), and poly(caprolactone).12,13 Cargo release from biodegradable 
systems is typically controlled by the degradation rate of the encapsulating polymer.12,13 
Dissolvable materials are linear, uncrosslinked polymers, such as poly(vinyl pyrrolidone), 
poly(vinyl alcohol), and poly(acrylic acid), that are soluble in aqueous environments, where they 
rapidly release encapsulated cargo.14   
 When designing a microneedle patch for delivery of a specific encapsulated therapeutic, 
the material composition of the microneedle must be carefully considered. The microneedle 
material should be compatible with the encapsulated therapeutic, both in terms of solubility and 
stability of the therapeutic in the material. The release properties of the material should also be 
compatible with the desired release rate of the drug. In this chapter, we demonstrate the ability to 
fabricate microneedles from a library of drug-releasing materials with swellable, degradable, and 
dissolvable release mechanisms. Model small molecule and protein cargoes were encapsulated 
within the drug-releasing microneedles, and the release rates and compatibility of the model 
cargoes with the drug-releasing microneedle materials was explored.  
3.2 Materials and Methods 
3.2.1 Materials 
 Poly(ethylene glycol) dimethacrylate (Mn = 550) (PEG 550), poly(ethylene glycol) 
methyl ether methacrylate (Mn = 1100) (PEGMA), diphenyl(2,4,6-trimethylbenzoyl)phosphine 
oxide (TPO), fluorescamine, sucrose, lysozyme from chicken egg white, and phosphate buffered 
saline (pH = 7.4) (PBS) were obtained from Sigma Aldrich. Poly(ethylene glycol) dimethacrylate 
(Mn = 350) (PEG 350) was obtained from TCI America. Glutaraldehyde 25% solution was 
obtained from Fisher Scientific. Fluorescein isothiocyanate bovine serum albumin conjugate 
(FITC-BSA), DyLight 550 N-hydroxysuccinimide (NHS) ester, and gel electrophoresis supplies 
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including Novex NuPAGE 4-12 % Bis-Tris gels, MES SDS running buffer, and Coomassie R-
250 were obtained from Thermo Fisher Scientific. Acrylic acid and rhodamine B base were 
obtained from Acros Organics. Green tissue marking dye, Cryo-Kit H&E Staining Kit, and 
Frozen-Fix were obtained from Cancer Diagnostics. Tissue-Tek optimum cutting temperature 
compound was obtained from Sakura Finetek. Paraformaldehyde solution, 4% in PBS, was 
obtained from Affymetrix USB. EnzChek Lysozyme Assay Kit was obtained from Molecular 
Probes. DetectX Butyrylcholinesterase Fluorescent Activity Kit was obtained from Arbor 
Assays. Poly(caprolactone) trimethacrylate (Mn = 1100) (PCL) and poly(L-lysine)-g-
poly(ethylene glycol) (PLL-g-PEG) were synthesized in house as previously described.7,15 
3.2.2 Microneedle Fabrication  
3.2.2.1 Blank Drug Releasing Microneedles  
 Square pyramidal microneedle computer-aided design (CAD) files were produced using 
SolidWorks 2014. Microneedles were 1000 µm tall and 333 µm wide at the base with 333 µm 
spacing between needles. Microneedle patches consisted of an array of 8x8 needles on a 6x6x1 
mm base. The microneedle CAD files (.STL) were then sliced at 1 µm thickness using Slic3r 
software. To make pre-microneedle resins, PCL, PEG 350, PEG 550, and acrylic acid, were each 
mixed with 2.5 wt% of the photoinitiator TPO. Microneedles were fabricated from the pre-
microneedle resins using the CLIP7, a prototype additive manufacturing system (Carbon), at a 
speed of 25 mm/hour and 1.9, 1.5, 1.2, and 8.9 mW/cm2 of light (l = 370 nm) for the PEG 350, 
PEG 550, PCL, and poly(acrylic acid) (PAA) microneedles, respectively. To ensure dimensional 
accuracy of the microneedles, CAD files were scaled along the Z-axis prior to fabrication by 
factors of 1.25, 1.175, 1.175, and 1.6 for the PEG 350, PEG 550, PCL, and PAA microneedles, 
respectively. PCL microneedle patches were briefly rinsed with acetone, and all other 
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microneedle compositions were briefly rinsed with isopropanol. Microneedles were post-cured 
for 10 minutes with a nitrogen-purged mercury UV lamp (l = 365 nm).  
3.2.2.2 Cargo-Loaded Microneedles 
 Cargo-loaded microneedles were fabricated using each of the previously described resins 
containing 0.1 wt% rhodamine B base as a fluorescent small molecule drug surrogate. For 
protein cargo loading and release assessment, FITC-BSA and lysozyme were loaded in the pre-
microneedle resin at 0.1-5 wt%. To isolate the cargo to only the needles of the patch, the base of 
the patch was fabricated with blank resin using the fabrication parameters described above. 
Following base fabrication, the build elevator was lifted, and the resin was exchanged for cargo-
loaded resin, which was then used to fabricate the needles of the patch.   
3.2.3 Microneedle Characterization  
 Microneedle patches were imaged using an environmental scanning electron microscope 
(ESEM) (FEI Quanta 200) in low vacuum mode to visualize morphology. The solubility of 
fluorescent cargo in pre-microneedle resins and distribution of fluorescent cargo within 
microneedles was assessed using confocal fluorescence microscopy (Zeiss LSM 700). 
Dissolution of cargo-loaded PAA microneedles was assessed by dissolving the microneedle 
patches in 10 mL of PBS, with imaging of the microneedle patch before and after dissolution 
using a Leica MZ16FA macroscope.  
3.2.4 Murine Skin Penetration 
 To test for skin penetration, blank microneedle patches of each composition were applied 
to excised murine skin with the permission of the UNC Institutional Animal Care and Use 
Committee (IACUC). Skin was excised from the back of nude mice (nu/nu), flash frozen, and 
stored at -20 °C until testing. Skin was thawed at room temperature, then fixed to a corkboard 
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using pins. Microneedle patches were applied to the skin using force of thumb for 10 seconds, 
followed by patch removal from the skin. A 1:1 mixture of isopropanol and green tissue marking 
dye was applied to the microneedle-treated skin for 3 minutes, then wiped away. Murine skin 
that was not exposed to microneedles was used as a control. Microneedle penetration of the skin 
was visualized using a Leica WILD M420 macroscope.  
 To visualize microneedle penetration within the skin, PAA microneedles were applied to 
excised nude murine skin for 10 seconds. For visualization of dye release in skin, 0.1 wt% 
rhodamine B base-loaded PAA microneedles were applied to murine skin for 30 minutes. After 
microneedle removal, skin was fixed in 2 % paraformaldehyde in PBS for 2 hours at 4 °C then 
stored in a 15 % sucrose in PBS solution at 4 °C until analysis. The murine skin was embedded 
in optimum cutting temperature compound and cryosectioned into 12 µm sections using a Leica 
Cryostat at -25 °C. For microneedle penetration visualization, skin sections were hematoxylin 
and eosin stained, then imaged using brightfield microscopy (Olympus BX61 Upright Wide 
Field Microscope). For dye release visualization, skin sections were fixed in Frozen-Fix for 10 
seconds, then imaged using fluorescence microscopy (Olympus BX61 Upright Wide Field 
Microscope). 
3.2.5 Rhodamine Release Kinetics in Solution 
 Microneedle patches of each drug-releasing composition containing 0.1 wt% rhodamine 
B base were fabricated. Microneedle patches were submerged in 1 mL of PBS in Eppendorf 
tubes, which were placed in a water bath maintained at 37 °C. At time points over the course of 
168 hours for PEG and PCL compositions and over the course of 1 hour for the PAA 
composition, 500 µL of PBS was removed and replaced with an equal volume of fresh PBS. 
Rhodamine release was quantified by measuring the fluorescence of the PBS removed at each 
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time point using a plate reader (SpectraMax M5, Molecular Devices), with excitation at 544 nm 
and emission at 590 nm. Fluorescence signal was correlated to concentration of rhodamine using 
a standard curve and expressed as percent of theoretical rhodamine loading in the microneedles 
released at each time point.  
3.2.6 Lysozyme Activity in Microneedles 
 PAA and PEG 550 microneedles containing 1 wt% lysozyme were fabricated. Lysozyme-
loaded microneedle patches were placed in 1 mL of PBS maintained at 37 °C for 24 hours to 
allow the PAA microneedles to dissolve and the PEG 550 microneedles to release loaded 
lysozyme. Lysozyme activity in the pre-microneedle resins and after release from microneedles 
was compared to the activity of lysozyme in PBS measured using an EnzChek Lysozyme Assay 
Kit according to the manufacturer’s instructions. Briefly, lysozyme-containing samples were 
incubated with fluorescein labeled micrococcus lysodeikticus. Lysozyme cleaves the 1,4-b-
linkages between N-acetylmuranic acid and N-acetyl-D-glucosamine in the bacterial cell walls, 
which relieves quenching of the fluorescent signal and results in an increase in fluorescence that 
correlates with lysozyme activity. Fluorescence of the samples was measured using a plate reader 
(SpectraMax M5, Molecular Devices) with excitation at 494 nm and emission at 518 nm and 
correlated to fluorescence of a lysozyme standard curve to calculate activity. Lysozyme activity 
in each sample was controlled for lysozyme mass in the sample as determined by a 
fluorescamine assay.16 150 µL of lysozyme sample was mixed with 50 µL of a 3 mg/mL 
fluorescamine in acetone solution, and the fluorescence was read at 400 nm excitation and 460 
nm emission using a plate reader (SpectraMax M5, Molecular Devices).  
3.2.7 Lysozyme Stability Screen under CLIP Conditions 
 To determine the effect of exposure to CLIP conditions on the stability of proteins, a 
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stability screen using lysozyme as a model protein cargo was conducted. Solutions containing 1 
wt% lysozyme in combination with 0-2.5 wt% TPO and 0-96.5 wt% monomers acrylic acid or 
PEGMA were prepared in duplicate. Monofunctional PEGMA was used in this experiment to 
prevent crosslinking and facilitate protein recovery. One sample of each prepared solution was 
not exposed to UV light, while the other sample was exposed to UV light (l = 385 nm) at 7 
mW/cm2 for 30 seconds. Following light exposure, samples were dissolved in PBS. Lysozyme 
activity in each sample was assessed using an EnzChek Lysozyme Assay Kit, and lysozyme 
concentration in each sample was measured using a fluorescamine assay, as previously 
described. Lysozyme activity was calculated in terms of units of activity per mass of lysozyme 
present in the sample and expressed as percent activity retained compared to free lysozyme in 
PBS.  
 Structural stability of the lysozyme samples was analyzed by non-reducing sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using an XCell SureLock Mini-
Cell (Thermo Fisher Scientific) and NuPAGE Novex 4-12 % Bis-Tris gels. Manufacturer’s 
instructions for SDS-PAGE protocol were followed; however, the protein samples were not heat 
denatured before analysis in order to retain the protein conformation.17 8 µg of each sample was 
loaded into the gel, which was run at 200 V for 35 minutes using MES SDS running buffer. Gels 
were stained with Coomassie R-250 to visualize protein bands.  
3.2.8 BuChE Nanozyme Fabrication  
 Equine butyrylcholinesterase (BuChE) was labeled with DyLightÔ 550 NHS ester per 
the manufacturer’s instructions at a 3-fold molar excess of dye to protein. BuChE nanozymes 
containing both DyLight 550-labeled BuChE and unlabeled BuChE were prepared as described 
by Gaydess et al.15 Solutions of PLL-g-PEG and BuChE were prepared in 10mM phosphate 
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buffer (pH 7.4) at concentrations of 0.35 mg/mL for the PLL-g-PEG and 0.45 mg/mL for the 
BuChE. PLL-g-PEG and BuChE solutions were mixed at a 2:1 ratio and allowed to sit at room 
temperature for 1 hour to form the uncrosslinked nanozyme. The BuChE nanozyme was 
crosslinked by the addition of glutaraldehyde at a 40 % molar ratio of aldehyde groups to lysine 
residues. After adding glutaraldehyde to the nanozyme solution, the crosslinking reaction was 
allowed to proceed at room temperature for 5 hours.  
3.2.9 BuChE Nanozyme-Loaded Microneedle Fabrication and Characterization 
 PAA microneedles containing free equine BuChE, uncrosslinked BuChE nanozyme, and 
40 % crosslinked BuChE nanozymes at 1 wt% were fabricated as described above. DyLight 550-
labeled free BuChE and BuChE nanozyme-loaded PAA microneedles were imaged with ESEM 
in low vacuum mode (FEI Quanta 200) to visualize microneedle morphology and confocal 
fluorescence microscopy (Zeiss LSM 700) to visualize BuChE distribution in the microneedles. 
PAA microneedles containing unlabeled BuChE and BuChE nanozymes were dissolved in water 
to release the encapsulated BuChE for activity assessment.  
3.2.10 BuChE Activity Assessment  
 Samples containing free BuChE, uncrosslinked BuChE nanozyme, and 40 % crosslinked 
BuChE nanozyme in water, in the acrylic acid pre-microneedle resin, and after release from PAA 
microneedles were prepared. BuChE activity was measured using a DetectX 
Butyrylcholinesterase Fluorescent Activity Kit per the manufacturer’s instructions. Briefly, 
BuChE-containing samples were mixed with a butyrylthiocholine iodide substrate and ThioStar 
Reagent. The BuChE cleaves the butyrylthiocholine iodide substrate, producing a thiol product 
which reacts with the ThioStar Reagent to produce a fluorescent product. The fluorescence of the 
product is directly proportional to the activity of the BuChE in the sample. Fluorescence of the 
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BuChE samples was read at 390 nm excitation and 510 nm emission using a plate reader 
(SpectraMax M5, Molecular Devices) and correlated to the fluorescence of an equine BuChE 
standard curve to calculate the activity. BuChE mass in the samples was determined using a 
fluorescamine assay as previously described. BuChE in each activity sample was correlated with 
BuChE mass in the sample and expressed as percent activity retained compared to free BuChE in 
water.  
3.3 Results and Discussion 
3.3.1 Drug-Releasing CLIP Microneedle Matrices 
 Three photopolymerizable materials with differing cargo release properties were selected 
for fabrication of CLIP microneedles for encapsulated drug delivery: poly(ethylene glycol) 
dimethacrylate (PEG), poly(caprolactone) trimethacrylate (PCL), and acrylic acid. Each of the 
selected polymers are precursors to or photopolymerizable derivatives of GRAS (generally 
regarded as safe) materials commonly used in drug delivery applications. PEG forms a 
crosslinked network during polymerization and is expected to release cargo through swelling of 
the matrix upon insertion into skin. The crosslink density of the PEG network can be controlled 
by altering the molecular weight of the PEG chains, providing further control over cargo release 
rates.18 To investigate the effect of crosslink density on cargo release rates, two molecular 
weights of PEG, 350 g/mol (PEG 350) and 550 g/mol (PEG 550), were used to fabricate drug-
releasing microneedles. PCL forms a hydrophobic crosslinked network, ideal for drug release 
through sustained degradation of the material. Acrylic acid polymerizes into linear poly(acrylic 
acid) (PAA), a water-soluble polymer that dissolves when inserted into skin, quickly releasing 
encapsulated cargo. Microneedles were successfully fabricated from PEG 350, PEG 550, PCL, 
and PAA using CLIP (Figure 3.1). These drug releasing microneedles had a height of 1000 µm 
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and base width of 333 µm, with 333 µm interneedle spacing.  
 
Figure 3.1 Drug Releasing CLIP Microneedles. ESEM images of (A) PEG 350, (B) PEG 550, 
(C) PCL, and (D) PAA microneedles produced using CLIP. Scale bars measure 500 µm.  
 
 For microneedles to successfully deliver a therapeutic, the needles must have the 
mechanical strength to pierce skin. Microneedles of each of the drug releasing compositions 
were applied to excised nude murine skin. Murine skin is commonly used as a membrane for 
preclinical transdermal drug delivery studies and was used in this experiment due to its 
availability.19 Microneedles were applied to the murine skin using force of thumb for 10 seconds. 
Microneedles were then removed, and the skin was stained with a green tissue marking dye that 
selectively stains cells beneath the stratum corneum, indicating sites of microneedle penetration. 
Microneedles composed of both molecular weights of PEG, PCL, and PAA were able to 
successfully pierce murine skin, while skin that was not exposed to microneedles showed no 
sites of penetration (Figure 3.2). This ability to pierce skin with a short application time suggests 
these microneedles have promise for drug delivery applications. 
 
A B C D
 68 
 
Figure 3.2 Microneedle Skin Penetration. Penetration of excised murine skin is visible after 
application of (A) PEG 350, (B) PEG 550, (C) PCL, and (D) PAA microneedles and staining 
with tissue marking dye. (E) No sites of penetration are observed on control murine skin with no 
microneedles applied. Scale bars measure 1 mm.  
 
3.3.2 Characterization of Fluorescent Drug Surrogate Release from CLIP Microneedles 
 To assess the ability to load and release cargo from CLIP microneedles, drug-releasing 
CLIP microneedles of each composition were fabricated with the model small molecule drug 
surrogate rhodamine B base at 0.1 wt% loading (Figure 3.3). The rhodamine showed even 
distribution throughout the microneedles for each of the four polymeric compositions. The 
release kinetics of rhodamine from the drug releasing microneedles in aqueous solution were 
measured over time (Figure 3.4). The swellable and degradable PEG and PCL microneedle 
compositions were found to slowly release drug over the course of 1 week in solution. The PEG 
550 composition showed the highest release with 6 % of the loaded dose released after 1 week, 
while the PEG 350 and PCL compositions had more limited release at less than 1 % of the 
loaded dose released at 1 week. The more tightly crosslinked PEG 350 microneedle composition 
showed more limited release than the higher molecular weight PEG 550 composition, 







Figure 3.3 Rhodamine-Loaded Drug Releasing Microneedles. ESEM (top) and confocal 
fluorescence (bottom) images of PEG 350, PEG 550, PCL, and PAA microneedles loaded with 
0.1 wt% rhodamine. Scale bars measure 500 µm. 
 
 
Figure 3.4 Rhodamine Release Kinetics from Microneedles in Solution. Release rates of 
rhodamine from (A) PEG 350, PEG 550, and PCL microneedles over the course of 1 week and 
from (B) PAA microneedles over the course of 1 hour (n = 3).  
 
 The morphology of the PEG and PCL microneedles was retained after 1 week in solution 
(Figure 3.5). The rhodamine fluorescent signal also showed a similar intensity in the PEG 350 
and PCL compositions after release, while the PEG 550 microneedles had reduced fluorescent 




with the swellable and degradable microneedle compositions, the PAA microneedles rapidly 
dissolved in aqueous solution, releasing all loaded rhodamine after 15 minutes (Figure 3.4B). 
After 15 minutes in PBS, complete dissolution of the rhodamine-loaded PAA microneedles was 
visually observed, leaving behind the PCL microneedle base (Figure 3.6).  
 
Figure 3.5 Rhodamine-Loaded Microneedles After 1 Week in Solution. ESEM (top) and 
confocal fluorescence (bottom) images of rhodamine-loaded PEG 350, PEG 550, and PCL 
microneedles after 1 week in PBS. Scale bars measure 500 µm.  
 
 
Figure 3.6 PAA Microneedle Dissolution. (A) Rhodamine-loaded PAA microneedles on a PCL 






 The differences in rhodamine release rates observed among the PEG, PCL, and PAA 
drug encapsulating microneedle materials demonstrate the effect microneedle composition has 
on how microneedles release cargo. The dissolvable PAA microneedles showed the most rapid 
and complete cargo release in solution, making the PAA microneedle matrix the ideal choice for 
applications where quick therapeutic efficacy is desired. The slow releasing PEG and PCL 
compositions are better suited for long term, sustained release applications, where a low dose of 
therapeutic is needed over the course of weeks to months. As many microneedle applications 
necessitate quick release of the loaded therapeutic from the microneedle matrix, the dissolvable 
PAA microneedles were selected for further characterization of their ability to release cargo ex 
vivo. Blank and 0.1 wt% rhodamine-loaded PAA microneedles were applied to excised murine 
skin for 10 seconds and 30 minutes, respectively. After application, the patches were removed, 
and the skin was fixed and cryosectioned. The blank PAA microneedle-pierced skin was stained 
with hematoxylin and eosin (H&E) and imaged to visualize sites of microneedle disruption of the 
stratum corneum, while the rhodamine-loaded PAA microneedle-pierced skin was imaged using 
fluorescence microscopy to visualize dye release within the skin. Microneedle-mediated skin 
penetration and release of the rhodamine was observed in microneedle-treated skin, while no 
disruption of the skin and no dye release was observed in untreated skin (Figure 3.7). These 
results demonstrate that dissolvable CLIP microneedles are capable of delivering encapsulated 
therapeutic cargo to the skin in a short period of time, suggesting they hold promise for rapid 
drug delivery applications.  
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Figure 3.7 Murine Skin Penetration and Cargo Release. Ex vivo murine skin sections H&E 
stained after (A) PAA microneedle application and (B) no microneedle application. Murine skin 
sections after application of (C) fluorescent rhodamine-loaded microneedles and (D) no 
microneedle application. Scale bars measure 100 µm.  
 
3.3.3 Fabrication and Characterization of Protein-Loaded Microneedles 
 The administration of biotherapeutic molecules, particularly protein-based therapeutics, is 
one of the most promising uses of microneedles for drug delivery. After demonstrating that CLIP 
microneedles of a variety of drug-releasing polymeric compositions can be successfully loaded 
with and release the model drug surrogate rhodamine both in solution and in skin ex vivo, we 
investigated the utility of these microneedles for protein delivery applications. The model protein 
bovine serum albumin (BSA) was used for initial protein loading studies in the PEG microneedle 
compositions. Both PEG 350 and PEG 550 microneedles were fabricated with fluorescently-
labeled FITC-BSA at 0.1 wt% loading (Figure 3.8). Both PEG microneedle compositions 
showed punctate distribution of the FITC-BSA protein within the needles. The higher molecular 
weight, lower crosslink density PEG 550 microneedles appeared to have more protein cargo 
loaded in the needles compared to the more tightly crosslinked PEG 350 microneedles. 




When PEG 350 microneedles were fabricated with higher loadings of BSA up to 5 wt%, the 
aggregation of the protein on the surface of the microneedles become more pronounced (Figure 
3.9).  
 
Figure 3.8 BSA-Loaded PEG Microneedles. ESEM (top) and confocal fluorescence (bottom) 
images of PEG 350 and PEG 550 microneedles loaded with 0.1 wt% FITC-BSA. Scale bars 
measure 500 µm.  
 
 
Figure 3.9 BSA Loading Optimization in PEG Microneedles. ESEM (top) and confocal 
fluorescence (bottom) images of PEG 350 microneedles loaded with 0.5 wt%, 1 wt% and 5 wt% 




 We hypothesized that the punctate distribution of the protein cargo within the 
microneedles and aggregation on the microneedle surface was due to limited solubility of the 
hydrophilic BSA in the PEG resins. While PEG alone is a hydrophilic polymer, the addition of 
the methacrylate functional groups necessary for photopolymerization impart hydrophobicity to 
the low molecular weight PEG. This hypothesis was confirmed when the FITC-BSA-loaded 
PEG pre-microneedle resins were observed with confocal fluorescence microscopy, revealing the 
insolubility of BSA in the PEG resins compared to complete solubility in aqueous solution 
(Figure 3.10). 
 
Figure 3.10 Solubility of BSA in PEG Resins.  Confocal fluorescence images of FITC-BSA in 
(A) PBS, (B) PEG 350 pre-microneedle resin, and (C) PEG 550 pre-microneedle resin.  
 
 Due to the insolubility of hydrophilic cargo in the PEG microneedles, alternative 
microneedle compositions were explored for protein delivery applications. The pre-microneedle 
resin should be hydrophilic to increase the solubility of hydrophilic protein cargo in the resin, 
which could in turn improve distribution of the protein within the microneedle after 
photopolymerization. Of the remaining drug-releasing microneedle compositions, PAA was most 
suited for protein delivery due to the hydrophilicity of the acrylic acid monomer that comprises 
the pre-microneedle resin. Fluorescent FITC-BSA showed complete solubility in the acrylic acid 
pre-microneedle resin and more homogenous distribution throughout the solid microneedles 
compared to the PEG compositions (Figure 3.11). BSA-loaded PAA microneedles were found to 
completely dissolve in aqueous solution in less than 15 minutes, leaving behind the water-
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insoluble PEG base (Figure 3.12). Dissolvable PAA microneedles can successfully be fabricated 
with encapsulated model protein cargo, which is rapidly released in an aqueous environment.  
 
Figure 3.11 BSA-Loaded PAA Resin and Microneedles. (A) Confocal fluorescence image of 
FITC-BSA in acrylic acid pre-microneedle resin. (B) ESEM image of 1 wt% FITC-BSA-loaded 
PAA microneedles. (C) Confocal fluorescence image of 1 wt% FITC-BSA-loaded PAA 
microneedles. Scale bars measure 500 µm.  
 
 
Figure 3.12 Dissolution of BSA-Loaded PAA Microneedles. 1 wt% FITC-BSA-loaded PAA 
microneedles on a PEG 550 base (A) before and (B) after 15 minutes in PBS. Scale bars measure 
1 mm.  
 
3.3.4 Protein Stability in CLIP Microneedles 
 For proteins to be effective as therapeutics, they must retain their structure and activity 
during the formulation process. While using CLIP to fabricate drug-loaded microneedles avoids 
exposing cargo to extreme physical conditions, it does carry the potential to chemically alter 
loaded cargo through exposure to monomers, photoinitiators, UV light, and the free radical 
photopolymerization process. When proteins are subjected to free radical photopolymerization, 
they can be structurally altered through interaction with free radicals or through conjugation of 
the protein to a polymer chain, which can negatively impact a protein’s therapeutic activity or 




microneedles, PEG 550 and PAA microneedles were fabricated containing 1 wt% of the model 
enzyme lysozyme. The activity of the lysozyme was measured both in the pre-microneedle resin 
and after release from the microneedles. For both compositions, the activity of the lysozyme was 
retained in the pre-microneedle resin, but decreased greatly after release from cured 
microneedles, with 56 % of the original lysozyme activity retained for the PEG 550 composition 
and 19 % of original lysozyme activity retained for the PAA composition (Figure 3.13).  
 
Figure 3.13 Lysozyme Activity in PEG and PAA Microneedles. 1 wt% lysozyme-loaded (A) 
PEG 550 and (C) PAA microneedles. Enzymatic activity of lysozyme in (B) PEG 550 and (D) 
PAA pre-microneedle resins and after release from microneedles (n = 3). Scale bars measure 
500µm. 
 
 This drastic decrease in activity of a loaded cargo upon release from CLIP microneedles 
could be attributed to one or more of the components of the photopolymerizable system: (1) the 
monomer, (2) the photoinititator, or (3) the presence of UV light. To further investigate the cause 






of these components of CLIP microneedle fabrication either alone or in combination with one 
another in a protein stability screen. Solutions were prepared of lysozyme alone in PBS, in PBS 
with the photoinitiator TPO, in acrylic acid or poly(ethylene glycol) methyl ether methacrylate 
(PEGMA) (Mn = 1100) monomers, or in the pre-microneedle resins containing the monomers 
and TPO (Table 3.1). Solutions were then either not exposed to UV light or exposed to UV light 
for 30 seconds to simulate CLIP curing conditions. A monofunctional PEG methacrylate was 
utilized in this experiment to ensure the PEG did not cure when exposed to UV light and the 
lysozyme could be completely recovered for analysis. Lysozyme in each sample was analyzed 
using an activity assay to assess protein function and non-reducing SDS-PAGE to assess 
molecular weight and conformational changes.  
Table 3.1 CLIP Stability Screen Conditions.  
 
 In the stability screen using PEGMA as the monomer, no one component or combination 
of components of the CLIP fabrication process caused a greater than 30 % decrease in lysozyme 
activity or a visible change in protein molecular weight (Figure 3.14). The difference in 
lysozyme activity seen in this screen compared to the more drastic decrease observed when 
lysozyme was released from PEG 550 microneedles could be attributed to a number of factors. 
The static UV exposure and use of a monomethacrylated PEG make this screen not completely 
representative of the conditions the protein encounters during microneedle fabrication. The 
monofunctional PEG used in the stability screen also has a higher molecular weight than the 
difunctional PEG used to fabricate the PEG 550 microneedles, which could sterically hinder the 
Sample 1 2 3 4 5 6 7 8
Photoinitiator - - + + - - + +
Monomer - - - - + + + +
UV light - + - + - + - +
Protein + + + + + + + +
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reaction of PEG with the protein. While a decrease in lysozyme activity was not observed under 
the stability screen conditions, the protein still has the potential to conjugate to the methacrylated 
PEG and become trapped within the microneedle matrix, resulting in decreased bioavailability of 
the encapsulated protein.17 
 
Figure 3.14 Lysozyme Stability Screen in PEGMA. (A) Enzymatic activity (n = 3) and (B) 
SDS-PAGE of lysozyme after exposure to CLIP conditions in the PEG stability screen.  
 
 The stability screen using acrylic acid as the monomer only showed a large decrease in 
lysozyme activity when the lysozyme was exposed to UV light in the presence of both the 
photoinitiator and the monomer, which is the combination of components necessary to fabricate 
a CLIP microneedle (Figure 3.15A). This suggests that it is not one factor alone, but the free 
radical photopolymerization process itself that is damaging the encapsulated protein. An increase 
in lysozyme molecular weight was also observed for the sample containing the protein with the 
photoinitiator, monomer, and UV light, suggesting the PAA is polymerizing to the lysozyme or 
the lysosome is being structurally altered in another manner after exposure to free radical 
photopolymerization (Figure 3.15B). Conjugation of a polymer chain to the protein during free 
radical polymerization could be more likely with PAA than with PEGMA due to molecular 
A. B.
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weight differences. The low weight acrylic acid monomer and the low molecular weight PAA 
chains generated during photopolymerization have the potential to more easily react with the 
protein than the higher molecular weight PEGMA due to less steric hindrance and more 
abundant (meth)acrylate functional groups. From this experiment, we can conclude that 
encapsulation of a protein within PAA CLIP microneedles can result in alteration of the protein’s 
structure and function.  
 
Figure 3.15 Lysozyme Stability Screen in PAA. (A) Enzymatic activity (n = 3) and (B) SDS-
PAGE of lysozyme after exposure to CLIP conditions in the PAA stability screen.  
 
 There are several examples of free radical photopolymerized systems for the delivery of 
biologic cargo, particularly proteins for tissue engineering applications.22,23 However, most 
examples of protein delivery with photopolymerized systems involve hydrogels formed through 
solution polymerization, with a low concentration of a high molecular weight monomer in 
another solvent such as water.17,24 CLIP microneedle fabrication is a form of bulk 
polymerization, where a photoinitiator is added to a pure monomer, followed by induction of 
polymerization with the addition of UV light to generate a highly crosslinked system.  More 
densely crosslinked networks, such as those formed with bulk polymerization, have earlier 
radical diffusion limitation and higher propagating radical concentrations, which can result in 
A. B.
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increased damage to encapsulated biologic cargo.25 In this case, alternative measures must be 
taken to prevent alteration of loaded cargo.  
 One way to prevent damage to the structure and function of encapsulated proteins during 
free radical photopolymerization is to physically shield the protein from the photopolymerization 
process. The protein can be formulated with sacrificial molecules that are altered during free 
radical polymerization while the protein itself is protected from the polymerizing environment. 
Some examples of protein protection strategies used in photopolymerized systems include 
formulating the model proteins horseradish peroxidase and a-glucosidase in gelatin granules,26,27 
lyophilizing vascular endothelial growth factor with protecting BSA,28 and formulating the 
model protein BSA with the chelator iminodiacetic acid and metal ions.29 In each case, 
formulation of the protein cargo with protecting molecules resulted in retention of protein 
activity and structure after release from photopolymerized systems.  
  The protein formulation utilized for initial investigations into physical cargo protection 
during CLIP microneedle fabrication was the nanozyme, a block copolymer-enzyme complex 
developed by Alexander Kabanov and colleagues.30 Nanozymes are formed through ionic 
interactions between proteins and polymers of opposite charges. One block of the copolymer is 
ionic, with the other block being hydrophilic. When the copolymer is mixed with a charged 
protein in solution, a complex is formed, with the protein and ionic block of the copolymer at the 
center and the hydrophilic block of the copolymer on the surface (Figure 3.16A). A number of 
enzymes have been formulated into nanozymes, including superoxide dismutase, catalase, and 
organophosphorus hydrolase.31,30,32 One enzyme of particular interest in our lab is 
butyrylcholinesterase (BuChE), an organophosphate nerve agent scavenger (Figure 3.16B). 
Butyrylcholinesterase has previously been formulated into a poly(L-lysine)-g-PEG (PLL-g-PEG) 
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nanozyme for delivery to the central nervous system.15 The BuChE nanozyme formulation can 
be crosslinked with glutaraldehyde to further improve stability of the complex.  
 
Figure 3.16. Butyrylcholinesterase Nanozyme Structure. (A) Formation of a nanozyme from 
ionic interactions between an enzyme and diblock copolymer. (B) Structure of tetrameric human 
butyrylcholinesterase. Images reproduced with permission from references 31 and 33, 
respectively.  
 
 Butyrylcholinesterase nanozymes were fabricated by mixing PLL-g-PEG diblock 
copolymer with equine BuChE. The BuChE nanozyme was then crosslinked at 40 % with the 
addition of glutaraldehyde. DyLight 550-labeled BuChE, uncrosslinked nanozyme BuChE, and 
40 % crosslinked nanozyme BuChE, were loaded into PAA CLIP microneedles. Microneedles 
containing each BuChE formulation were imaged to visualize microneedle morphology and 
cargo distribution. Both the free BuChE and BuChE nanozyme-loaded microneedles showed 
similar needle morphology, suggesting the addition of BuChE nanozyme does not interfere with 
microneedle fabrication (Figure 3.17). Fluorescent BuChE was distributed throughout the 




Figure 3.17 BuChE and BuChE Nanozyme-Loaded PAA Microneedles. ESEM and confocal 
fluorescence images of PAA microneedles loaded with (A,D) free BuChE, (B,E) uncrosslinked 
BuChE nanozyme, and (C,F) 40 % crosslinked BuChE nanozyme. BuChE is labeled with 
DyLight 550. Scale bars measure 500 µm.  
 
 The activity of BuChE was assessed in the free, uncrosslinked nanozyme, and 40 % 
crosslinked nanozyme formulations, either in solution, in the pre-microneedle acrylic acid resin, 
or after release from PAA microneedles. Compared to free BuChE in solution, the uncrosslinked 
nanozyme BuChE retained the majority of its activity, while BuChE in the 40 % crosslinked 
nanozyme in aqueous solution lost 89 % of its activity, and BuChE under all other conditions 
completely lost activity (Figure 3.18). The loss of BuChE activity when exposed to the acrylic 
acid pre-microneedle resin suggests the BuChE is destabilized when in contact with acrylic acid 
alone, and the nanozyme formulation was not sufficient to physically protect the BuChE from 
the resin or the free radical photopolymerization process. Exploration of alternative physical 
protection strategies will be necessary to potentially find a method to retain activity of 





Figure 3.18 Activity of BuChE and BuChE Nanozyme in PAA Microneedles. Enzymatic 
activity of free, uncrosslinked nanozyme, and 40 % crosslinked nanozyme-formulated BuChE in 




 In this work, we have demonstrated the ability to fabricate CLIP microneedles from 
swellable PEG, degradable PCL, and dissolvable PAA materials for encapsulated drug delivery 
applications. Microneedles of all compositions were loaded with the small molecule drug 
surrogate rhodamine, which released from the PEG and PCL microneedles in a sustained manner 
over the course of 1 week in solution and from the PAA microneedles rapidly and completely 
after 15 minutes in solution. The drug-releasing microneedles were able to penetrate murine skin, 
and the PAA microneedles were shown to release rhodamine within murine skin. The PEG and 
PAA compositions were used to encapsulate the model protein BSA, but insolubility of 
hydrophilic proteins in the PEG resins limit their use for encapsulated protein delivery 
applications. Loss of lysozyme activity was observed after release from the PEG and PAA 
microneedles. A protein stability screen under simulated CLIP conditions revealed the cause of 































process itself. Physical protection of encapsulated protein cargo during CLIP microneedle 
fabrication using a nanozyme formulation was explored, but activity of the nanozyme-formulated 
BuChE enzyme was not recovered after release from PAA microneedles. Drug-encapsulating 
CLIP microneedles show promise for drug delivery, but alternative physical protection methods 
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 Microneedles can be utilized to deliver therapeutics in a number of ways, including: (1) 
the “poke and patch” technique where solid microneedles are applied then removed, followed by 
application of a therapeutic to the area of the skin where microneedles were applied, (2) the 
“poke and flow” technique where hollow microneedles are inserted into skin, then a therapeutic 
solution is pumped or allowed to passively diffuse through the open channel of the microneedles, 
(3) the “coat and poke” technique where a therapeutic is coated on the surface of the 
microneedles, followed by insertion into the skin, where the coating dissolves and releases the 
therapeutic, and (4) the “poke and release” technique where the therapeutic is encapsulated 
within the microneedle matrix and releases through microneedle swelling, degradation, or 
dissolution after insertion into skin.1–3 Each of these classes of microneedles and drug delivery 
techniques have unique advantages and limitations. While the “poke and patch” and “poke and 
flow” techniques using solid and hollow microneedles are useful for delivering larger quantities 
of therapeutic, the multistep application process and more complicated nature of these 
microneedles have the potential to decrease their ease of use and patient compliance.1,3 The 
“poke and release” drug-encapsulating microneedles have the advantage of controlled 
therapeutic release and increased safety, but the therapeutic encapsulation method used to 
fabricate the microneedles must be compatible with the cargo.1 As discussed in Chapter 3, using 
free radical photopolymerized CLIP microneedles to encapsulate protein cargo has the potential
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 to alter the stability of the cargo, limiting their utility for biologic delivery. The “coat and poke” 
microneedles are restricted in the quantity of therapeutic they can deliver. However, coated 
microneedles are simple to use and compatible with biologic cargo, making them ideal for 
protein delivery with CLIP microneedles.3 
 Microneedles have been coated with therapeutics using a variety of techniques, including 
dip coating,4–6 spray coating,7,8 and inkjet printing.9,10 The most straightforward approach to 
coating microneedles is dip coating, where the microneedles are dipped into a liquid coating 
solution containing the therapeutic of interest, then removed. The liquid coating is allowed to 
dry, typically via air drying, producing a solid film of coating on the microneedles. 
 One limitation of using dip coating methods to coat microneedles is the potential for 
coating of the therapeutic on the base of the microneedle patch in addition to the needles. When 
microneedles are dipped into a liquid coating solution, their close spacing can cause the solution 
to be drawn up between the needles and to the base of the patch due to capillary action.4 As only 
the needles are inserted into skin, any drug coated on the base of the patch is not delivered. 
Microneedles have been found to only insert between 10 and 80 % of their full length into skin, 
so selectively coating only the portion of the needles that insert into skin would ensure a high 
portion of the coated therapeutic dose is delivered.11 
 A number of methods have been utilized to selectively coat the needles of microneedle 
patches by dip coating. These include using a high viscosity coating solution to reduce the effects 
of capillary action,5 dipping the microneedles into another solution-filled microneedle array of 
the same geometry,12 and using micropositioning devices to dip the microneedle patches into 
coating solutions at controlled heights, both into open solution reservoirs6,13,14 and into solution 
reservoirs covered by a plate containing dip holes through which the microneedles were 
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inserted.4 Using covered solution reservoirs for microneedle coating is a promising approach, as 
it provides a physical barrier between the microneedle base and the coating solution to minimize 
drug waste.  
 Using CLIP, we have the ability to rapidly fabricate covered coating solution reservoirs 
with designs specific to the microneedle patches they are intended to coat. These coating solution 
reservoirs, called coating mask devices, can be used to coat CLIP microneedles in a spatially 
controlled manner. In this chapter, we demonstrate the ability to coat CLIP microneedles with a 
variety of protein cargoes using CLIP-fabricated coating mask devices. The role of the coating 
mask device design in cargo localization and loading was explored, and the release kinetics and 
stability of protein cargo coated on the microneedles were assessed.  
4.2 Materials and Methods 
4.2.1 Materials 
Diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide (TPO), sucrose, methylcellulose 
(viscosity: 25 cP), bovine serum albumin (BSA), lysozyme from chicken egg white, ovalbumin 
from chicken egg white (OVA), recombinant human insulin, and phosphate buffered saline 
(PBS) (pH = 7.4) were obtained from Sigma Aldrich. Poly(ethylene glycol) dimethacrylate (Mn = 
350) (PEG 350) was obtained from TCI America. Glacial acetic acid was obtained from Fisher 
Scientific. AlexaFluor 488 bovine serum albumin conjugate (AF488-BSA), fluorescein 
isothiocyanate bovine serum albumin conjugate (FITC-BSA), and Coomassie Plus Assay 
Reagent were obtained from Thermo Fisher Scientific. Paraformaldehyde solution, 4% in PBS, 
was obtained from Affymetrix USB. Green tissue marking dye and Frozen-Fix were obtained 
from Cancer Diagnostics. Tissue-Tek optimum cutting temperature compound was obtained 
from Sakura Finetek. EnzChek Lysozyme Assay Kit was obtained from Molecular Probes. 
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4.2.2 Microneedle and Coating Mask Device Fabrication 
 Computer-aided design (CAD) files of microneedle patches and coating mask devices 
were produced using SolidWorks 2014. Microneedles were square pyramidal shaped, 1000 µm 
tall and 333 µm wide with 1000 µm spacing between needles. Microneedle patches consisted of 
an array of 8x8 needles on a 10x10x1 mm base. Coating mask devices consisted of an 8x8 array 
of 500x500 µm wells in a 10x10x0.5 mm plate, with a reservoir under the plate for the coating 
solution. Raised edges between 200 µm and 500 µm in height were included on the surface of 
the coating mask. Both microneedles and coating mask devices were fabricated from a resin 
composed of PEG 350 with 2.5 wt% TPO as a photoinitiator. Microneedles and coating masks 
were fabricated using the S1 additive manufacturing prototype system (Carbon) with a 1 µm 
slice thickness, speed of 12 mm/hour, and 4 and 1 mW/cm2 light intensity (l = 385 nm) for the 
microneedles and coating masks, respectively. To ensure dimensional accuracy, CAD files were 
scaled along the Z-axis by a factor of 1.3 prior to fabrication. After fabrication, microneedles and 
coating masks were briefly rinsed with isopropanol and post-cured for 5 minutes using a Phoseon 
FireJetÔ FJ800 UV LED lamp.  
4.2.3 Coating of CLIP Microneedles 
 Microneedle coating solutions were prepared by first dissolving 30 mg of methylcellulose 
in 1 mL of water with stirring at 85 °C for 1 hour, then incubated at 4 °C overnight. 300 mg of 
sucrose was added to the methylcellulose solution, which was mixed at room temperature until 
dissolved. Protein cargo, including BSA, AF488-BSA, FITC-BSA, and lysozyme, was then 
added to the coating solution at 0.7-7 wt% loading and mixed at room temperature until 
dissolved. To coat the microneedles, coating mask devices were filled with 100 µL of the coating 
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solution. Microneedle patches were inserted into the coating mask, held in the mask for 10 
seconds, then removed and allowed to dry at room temperature for 24 hours.  
4.2.4 Coating Mask Design Optimization 
 Coating masks with no raised edges and raised edges 200 µm, 300 µm, 400 µm, and 500 
µm in height were fabricated and used to coat microneedle patches with coating solutions 
containing 0.7 wt% AF488-BSA and 7 wt% BSA as model protein cargo. AF488-BSA-coated 
microneedles were imaged using environmental scanning electron microscopy (ESEM) (FEI 
Quanta 200) in low vacuum mode to visualize coating morphology and confocal fluorescence 
microscopy (Zeiss LSM 700) to assess fluorescent cargo distribution. The height of the BSA 
coating on the microneedles was measured from ESEM images using ImageJ software. 
Unlabeled BSA-coated microneedles were placed in 2 mL of water for 1 hour to dissolve the 
microneedle coating, and the BSA concentration on each microneedle patch was quantified using 
a Bradford assay following the manufacturer’s instructions. Briefly, 150 µL of Coomassie 
Protein Assay Reagent was added to 150 µL of sample, and the absorbance was read at 595 nm 
using a plate reader (SpectraMax M5, Molecular Devices). Absorbance was correlated to 
concentration of BSA using a standard curve.  
4.2.5 Coating Dissolution In Vitro and Ex Vivo 
 Microneedles were coated with a coating solution containing 0.7 wt% AF488-BSA using 
a coating mask with 300 µm raised edges. To assess dissolution of the coating in solution, 
patches were placed in 2 mL of water for 1 minute, 5 minutes, and 30 minutes before removal. 
Patches were imaged before and after dissolution in solution to visualize cargo release using 
ESEM in low vacuum mode (FEI Quanta 200), confocal fluorescence microscopy (Zeiss LSM 
700), and brightfield macroscopy (Leica WILD M420).  
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 To assess coating dissolution in skin, full thickness porcine skin obtained from Stellen 
Medical was utilized. AF488-BSA-coated microneedle patches were applied to excised porcine 
skin using force of thumb for 1 minute, then immediately removed or left in skin for a total time 
of 5 minutes or 30 minutes. Microneedle patches were imaged before and after insertion into skin 
to visualize coating dissolution using ESEM in low vacuum mode (FEI Quanta 200), confocal 
fluorescence microscopy (Zeiss LSM 700), and brightfield macroscopy (Leica WILD M420).   
Skin penetration was assessed by applying AF488-BSA-coated microneedle patches to 
full thickness porcine skin for 1 minute using force of thumb. The microneedle patch was 
removed, and the skin was stained with a 1:1 mixture of isopropanol and green tissue marking 
dye for 3 minutes before being wiped away with water. Microneedle penetration of the skin was 
visualized using a Zeiss Stemi 305 stereomicroscope. 
4.2.6 Lysozyme Microneedle Coating and Activity Measurement 
 A coating solution containing 7 wt% of lysozyme was prepared, then used to coat 
microneedles using a coating mask with 300 µm raised edges. Coated patches were imaged with 
ESEM (FEI Quanta 200) in low vacuum mode to visualize coating morphology. Lysozyme-
coated microneedles were placed in 2 mL of water for 1 hour to dissolve the protein coating from 
the patches. Activity of lysozyme in the coating solution and after release from coated 
microneedles was assessed using an EnzChek Lysozyme Assay Kit according to the 
manufacturer’s instructions as described in Chapter 3. Lysozyme activity in each sample was 
controlled for lysozyme concentration in the sample, which was measured using a Bradford 




4.2.7 BSA-Coated Microneedle Franz Diffusion Cell Assessment 
 Microneedle patches were coated with a coating solution containing 7 wt% FITC-BSA 
using a coating mask with 300 µm raised edges. To determine average FITC-BSA loading on the 
microneedle patches, patches were placed in 2 mL of water to dissolve the coating, and 
fluorescence of the solutions was measured using a plate reader (SpectraMax M5, Molecular 
Devices) with excitation at 494 nm and emission at 520 nm. Fluorescence was correlated with 
FITC-BSA mass on the microneedle patches using a standard curve.  
FITC-BSA-coated patches were applied to full thickness porcine skin using force of 
thumb for 1 minute, then left in the skin for an additional 4 minutes before removal. A 15 mm, 5 
mL jacketed Franz diffusion cell (PermeGear) was filled with PBS, and the microneedle-pierced 
porcine skin was placed between the donor and receptor chambers of the cell. The Franz 
diffusion cell was placed in a water bath at 37 °C, with stirring of the receptor chamber fluid at 
600 rpm. At time points over the course of 24 hours, 400 µL of receptor chamber fluid was 
removed and replaced with an equal volume of fresh PBS. A Franz diffusion cell with untreated 
porcine skin was run as a control. Fluorescence of the receptor chamber fluid was measured at 
each time point using a plate reader (SpectraMax M5, Molecular Devices) with excitation at 494 
nm and emission at 520 nm and correlated to FITC-BSA concentration using a standard curve. 
FITC-BSA concentration in the receptor chamber at each time point was expressed as percent of 
the original average FITC-BSA loading on the microneedle patch, as determined above.  
4.2.8 BSA Release in Porcine Skin 
 After termination of the Franz diffusion cell experiment at 24 hours, the microneedle-
pierced and untreated porcine skin was fixed in 2 % paraformaldehyde for 2 hours at 4 °C, then 
stored in 15 % sucrose in PBS at 4 °C until analysis. The skin was embedded in optimum cutting 
	 95 
temperature compound and cryosectioned into 12 µm sections. Skin sections were fixed in 
Frozen-Fix for 10 seconds, then imaged with differential interference contrast (DIC) and 
fluorescence microscopy using an Olympus BX61 Upright Wide Field Microscope to visualize 
FITC-BSA distribution in the skin.  
4.2.9 Coating of Microneedles with Protein Therapeutics 
 Microneedles were coated with ovalbumin using a coating solution comprised of 2 wt% 
methylcellulose, 35 wt% sucrose, and 6 wt% ovalbumin in water and with human insulin using a 
1 wt% acetic acid, 2 wt% methylcellulose, 35 wt% sucrose, and 0.6 wt% insulin aqueous coating 
solution. Ovalbumin and insulin microneedles were coated using coating masks with 300 µm 
raised edges. Coating morphology on the patches was visualized using ESEM (FEI Quanta 200) 
in low vacuum mode. Loading of ovalbumin and insulin on the microneedle patches was 
quantified after dissolution using a Bradford assay.  
4.2.10 Statistical Analysis 
 Statistical analysis was performed using GraphPad Prism 7 software. Unpaired t-tests 
were utilized to compare two groups, while one-way analysis of variance (ANOVA) with 
Tukey’s multiple comparisons tests were used to compare multiple groups. P values less than 
0.05 were considered statistically significant.  
4.3 Results and Discussion 
4.3.1 CLIP Microneedle Coating Process 
 For microneedles to be effectively coated, the coated therapeutic should be localized to 
the area of the needles that will be inserted into skin, which helps minimize drug waste and 
reduces dosing variability.4 In order to isolate microneedle coating to just the tips of the needles, 
a coating mask device was designed and fabricated using CLIP. The coating mask device 
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consists of a coating solution reservoir, which is covered by a plate with individual wells for 
each of the needles on the microneedle patch. Raised edges on the surface of the plate prevent 
contact between the base of the microneedle patch and the coating solution, ensuring only the 
needle tips are coated with therapeutic. Computer-aided design (CAD) files of the microneedle 
patches and coating mask devices utilized for coating microneedles in this chapter are shown in 
Figure 4.1. Both the microneedles and the coating mask devices were fabricated using a resin 
composed of poly(ethylene glycol) dimethacrylate (Mn = 350) (PEG 350) with 2.5 wt% TPO as a 
photoinitiator. PEG 350 was chosen as the material for coated microneedle and coating device 
fabrication due to its insolubility in water, mechanical strength, and status as a 
photopolymerizable derivative of a GRAS material.  
 
 
Figure 4.1 CAD Files of Microneedle Patch and Coating Mask Devices. CAD files of (A) 
8x8 array of 1000 µm tall, 333 µm wide square pyramidal microneedles with 1000 µm spacing 
between the needles on a 10x10x1 mm base, (B) coating mask device, with an 8x8 array of 
500x500 µm wells in a 10x10 mm plate over a coating solution reservoir, and (C) coating mask 
device with 300 µm raised edges.   
 
 Microneedles are typically coated with aqueous solutions containing the therapeutic of 
interest along with some combination of viscosity enhancers for coating thickness, surfactants 
for wettability, and cargo stabilizers.4,15 A number of viscosity enhancers have been utilized for 
microneedle coating, including carboxymethylcellulose, sodium alginate, and 






microneedles due to its status as a GRAS material and neutral charge, which ensures it will not 
ionically interact with other coating solution components. Sucrose was also included in the 
coating solution formulation for its viscosity enhancing and protein stabilizing properties.16,18,19 
Microneedles were coated with an aqueous coating solution containing methylcellulose 
and sucrose at 2 wt% and 21 wt%, respectively. The desired cargo was added to the coating 
solution, which was used to fill the coating mask device reservoir. The microneedles were coated 
using a dip coating process, where the microneedle patch was inserted into the solution-filled 
coating mask, held for 10 seconds, then removed and allowed to air dry (Figure 4.2).  
 
 
Figure 4.2 Microneedle Coating Method. PEG microneedles are inserted into a solution-filled 
coating mask device, then withdrawn and allowed to dry.  
 
4.3.2 Effect of Coating Mask Design on Microneedle Coating 
 To demonstrate the role the raised edge on the surface of the coating mask plays in the 
microneedle coating process, coating masks with no raised edges or with 300 µm raised edges 
were fabricated and used to coat microneedles with a coating solution containing 0.7 wt% 
AlexaFluor 488-BSA (AF488-BSA). When microneedles were coated using masks without 
raised edges, the base of the microneedle patch came into contact with the surface of the coating 
mask, and coating solution was drawn up between the needles due to capillary action. In this 
case, the majority of the coating solution and loaded AF488-BSA cargo ended up on the base of 
the microneedle patch (Figure 4.3A,C). When a coating mask with 300 µm raised edges was 
used to coat microneedles, the raised edges prevented the microneedle base from touching the 
coating solution. Only the tips of the microneedles were inserted into the coating solution, which 





Figure 4.3 Coating Mask Cargo Localization. ESEM and confocal fluorescence images of 
microneedles coated with AF488-BSA using coating masks with (A,C) no raised edges and 
(B,D) 300 µm raised edges. Scale bars measure 500 µm. 
 
 After demonstrating the ability to localize coated cargo to needles by using microneedle 
coating mask devices with raised edges, the ability to precisely control microneedle coating 
localization by altering the design of the coating mask was investigated. Coating mask devices 
with raised edges 200 µm, 300 µm, 400 µm, and 500 µm in height were fabricated and used to 
coat microneedles with a coating solution containing 0.7 wt% AF488-BSA. Differences in 
localization of the AF488-BSA coating were visually observed among microneedles coated 
using masks with different edge heights, with coating appearing to cover a smaller needle area as 
the coating mask edge height increased (Figure 4.4). Altering the height of the raised edge on the 
coating mask devices used to coat microneedles resulted in significantly different coating heights 
on the microneedles (p < 0.002), which corresponded with different BSA loadings on the 
microneedle patches (Figure 4.5). The height of the raised edge on the coating mask was 




coated on the patches, demonstrating control over both cargo localization and loading through 
coating mask design.  
 
 
Figure 4.4 Effect of Mask Edge Height on Microneedle Coating. ESEM (top) and confocal 
fluorescence (bottom) images of microneedles coated with AF488-BSA using coating masks 
with raised edges 200 µm, 300 µm, 400 µm, and 500 µm in height. The bottom edges of the 




Figure 4.5 Microneedle Coating Height and Cargo Loading. (A) Height of AF488-BSA 
coating (n = 8 needles) and (B) BSA loading on microneedles (n = 3 patches) coated using 



















































































 By using CLIP-fabricated coating mask devices to coat microneedles with cargo, we have 
the ability to localize coating to only the area of the needles inserted into skin with no deposition 
of coating on the base of the patch. While the depth microneedles penetrate in skin can vary 
widely depending on a number of factors, including patch design, application force, and skin 
thickness, no microneedles penetrate skin to their full length.1,11,20 Isolating the coated 
therapeutic to only the skin-penetrating area of the needles will minimize wasted therapeutic and 
ensure that a more consistent dose of the drug is administered.  
4.3.3 Characterization of Coating Dissolution 
  The kinetics of cargo release from coated microneedles were initially investigated in 
aqueous solution. Microneedles were coated with a 0.7 wt% AF488-BSA coating solution using 
a coating mask with 300 µm raised edges. Coated microneedles were placed in water for 1, 5, 
and 30 minutes, then removed and imaged to assess cargo dissolution. Compared to microneedle 
patches before dissolution, complete release of the cargo was observed after 1 minute in solution. 
The coating appeared to be dissolved from the needles, with no fluorescent signal from the 





Figure 4.6 Microneedle Coating Release in Solution. ESEM and confocal fluorescence images 
of AF488-BSA-coated microneedles (A,C) before and (B,D) after 1 minute in water. Scale bars 
measure 500 µm.  
 
 Cargo release kinetics were next assessed ex vivo in excised porcine skin. Porcine skin 
was utilized for this experiment as it is the most relevant model for human skin, with similar 
thickness, hair content, composition, and transdermal permeation rates to human skin.21,22 
AF488-BSA-coated microneedles were applied to full thickness porcine skin using force of 
thumb for 1 minute, then immediately removed or left in skin for a total time of 5 minutes or 30 
minutes before removal. After removal, patches were imaged to assess cargo distribution. After 1 
minute in porcine skin, the coating on the microneedles appeared to be dissolved, with the 
majority of the cargo released compared to patches before skin insertion (Figure 4.7). No further 
release was observed when coated microneedle patches were left in the porcine skin for longer 
periods of time (data not shown). This rapid cargo release is promising for a number of 
microneedle applications, including delivery of insulin and local anesthetics, which require quick 
onset of therapeutic action.23–25 Additionally, the rapid release will minimize the length of time 






Figure 4.7 Microneedle Coating Release Ex Vivo. ESEM and confocal fluorescence images of 
AF488-BSA-coated microneedle patches (A,C) before and (B,D) after insertion into porcine skin 
for 1 minute. Scale bars measure 500 µm. 
 
 Images of AF488-BSA-coated microneedle patches before dissolution, after 1 minute in 
water, and after 1 minute in porcine skin are shown in Figure 4.8A-C. Coating can be visually 
observed on the microneedle patch before dissolution, but has been released after 1 minute in 
aqueous solution or 1 minute in porcine skin. After application of the AF488-BSA-coated 
microneedle patch to porcine skin for 1 minute, the patch was removed, and the skin was stained 
with a green tissue marking dye to show sites of microneedle penetration. The coated PEG 350 
microneedles were successfully able to pierce porcine skin, suggesting these microneedles have 






Figure 4.8 Microneedle Coating Dissolution and Skin Penetration. Images of AF488-BSA-
coated microneedles (A) before dissolution, (B) after 1 minute in water, and (C) after 1 minute in 
porcine skin. (D) Porcine skin after AF488-BSA-coated microneedle skin penetration and 
staining with green tissue marking dye. Scale bars measure 1 mm.  
 
4.3.4 Protein Stability on Coated Microneedles 
 As discussed in Chapter 3, therapeutic cargoes must maintain their stability during 
microneedle formulation in order to be effective. Coating of microneedles after fabrication with 
CLIP prevents exposure of fragile protein cargo to free radical photopolymerization, which was 
shown to cause damage to encapsulated cargo. The dip coating method utilized to coat CLIP 
microneedles with cargo avoids subjecting the protein cargo to extreme physical conditions, but 
the process of air drying the protein coating on the microneedles has the potential to cause loss of 
protein activity and aggregation.15,26  
 To investigate the stability of proteins during the CLIP microneedle coating process, 
lysozyme was utilized as a model enzyme cargo. A coating solution containing 7 wt% lysozyme 
was prepared and used to coat microneedles. Activity of the lysozyme was measured in the 
coating solution and after release from coated microneedles and compared to the activity of 




solution and after release from coated microneedles (Figure 4.9). Lysozyme activity in the 
coating solution was increased compared to the activity of the lysozyme in aqueous solution. The 
observed retention of lysozyme activity after release from coated microneedles and increase in 
lysozyme activity in the coating solution are likely due to the stabilizing effects of sucrose in the 




Figure 4.9 Lysozyme Activity During Microneedle Coating. (A) ESEM image of lysozyme-
coated microneedles. Scale bar measures 500 µm. (B) Activity of lysozyme during microneedle 
coating, expressed as % activity retained compared to lysozyme in aqueous solution (n = 3).  
 
4.3.5 Ex Vivo Permeation of Coated Microneedle Protein Cargo 
Ex vivo permeation kinetics of FITC-BSA administered via coated microneedles through 
porcine skin were assessed using a Franz diffusion cell. Microneedles were coated with a coating 
solution containing 7 wt% FITC-BSA and applied to full thickness porcine skin using force of 
thumb for 1 minute. Patches were left in the skin for a total time of 5 minutes before removal. 
After patch removal, the skin was placed between the donor and receptor chambers of the Franz 




the course of 24 hours. Quick permeation of 21 % of the loaded FITC-BSA dose on the 
microneedle patch was observed in the first hour, with more sustained permeation through 24 
hours (Figure 4.10). A cumulative 42 % of the loaded FITC-BSA dose permeated through the 
porcine skin at 24 hours.  
 
 
Figure 4.10 Ex Vivo Permeation Kinetics of Coated Microneedle Protein Cargo. Permeation 
of FITC-BSA delivered from coated microneedle patches through porcine skin over 24 hours (n 
= 5).  
 
 After termination of the Franz diffusion experiment at 24 hours, the porcine skin was 
fixed and sectioned to assess FITC-BSA distribution in the skin. Sites of microneedle penetration 
were observed, with distribution of FITC-BSA in the epidermis and dermis (Figure 4.11A,C). 
Porcine skin that was not treated with microneedles showed no sites of skin penetration or FITC-
BSA signal after 24 hours on a Franz diffusion cell (Figure 4.11B,D). In the microneedle-treated 
skin, the FITC-BSA appeared to be concentrated in the epidermis, upper layers of the dermis, 
and around sites of microneedle penetration, with little fluorescent signal observed in the lower 
dermis. We hypothesize that the FITC-BSA coated near the tips of the microneedles quickly 
permeated the thickness of the porcine skin after application, as supported by the burst release 
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observed in the first hour of the Franz diffusion cell experiment. The FITC-BSA coated closer to 
the base of the microneedles remained around the sites of penetration and in the upper layers of 
the skin as seen in the skin sections, serving as a depot for the sustained permeation observed at 
later time points.  
 
 
Figure 4.11 Coated Microneedle Cargo Release. DIC and fluorescence overlay images of (A) 
porcine skin 24 hours after FITC-BSA-coated microneedle application and (B) untreated porcine 
skin. Fluorescence images of (C) porcine skin 24 hours after FITC-BSA-coated microneedle 
application and (D) untreated porcine skin. Scale bars measure 40 µm.  
 
Microneedle geometry, which includes factors such as needle height,20,27–29 needle 
density,27,30 shape,31,32 and tip radius,11,33 has been shown to play a role in how effective 
microneedles are at delivering therapeutics. In particular, needle height and density have been 
shown to be two of the main determinants in therapeutic delivery efficacy, with taller needles 
and lower needle densities providing the most enhanced drug permeation across skin.27,29 The tall 
needle height of 1000 µm and low needle density of 64 needles per cm2 utilized in this study 
likely contributed to the effectiveness of the microneedles at delivering a model protein cargo 
across full thickness porcine skin. While only one microneedle patch geometry was investigated 




determine the optimal microneedle geometry for enhanced skin permeation of specific cargoes.  
4.3.6 Therapeutic Protein-Coated Microneedles 
 Having demonstrated that CLIP microneedles can be coated with model protein cargoes 
with maintenance of protein activity and rapid release of the cargo in skin, the ability to coat 
microneedles with therapeutic protein cargoes was investigated. Two proteins were selected for 
microneedle coating: (1) ovalbumin (OVA) as a model vaccine antigen and (2) insulin for the 
treatment of diabetes. Both vaccine antigens and insulin require low doses by mass to be 
effective and are currently administered using hypodermic needle-based injections, making them 
ideal for delivery with microneedles.34,35 
 OVA was coated on microneedles using a coating solution consisting of 2 wt% 
methylcellulose, 35 wt% sucrose and 6 wt% OVA in water, while insulin was coated on 
microneedles with a 2 wt% methylcellulose, 35 wt% sucrose, 0.6 wt% insulin, 1 wt% acetic acid 
aqueous coating solution. The poor solubility of insulin prevented higher protein loading in the 
coating solution. Both OVA and insulin were successfully coated on microneedle patches, with a 
loading of 10.4 ± 1.9 µg per patch for OVA and 2.7 ± 0.2 µg (0.074 ± 0.006 IU) per patch for 
insulin (n = 3) (Figure 4.12).  
 
 
Figure 4.12 OVA and Insulin-Coated Microneedles. (A) OVA and (B) insulin-coated 




 One drawback of using coated microneedle patches to deliver a therapeutic is limited 
cargo loading, which is controlled by the surface area of the microneedle available for coating. 
Low solubility of the therapeutic can further limit the amount of drug that can be coated on the 
microneedle patches, as was the case with insulin. A number of opportunities exist for increasing 
the cargo loading on microneedle patches, including repeating the dip coating process multiple 
times to increase coating thickness and altering the design of the microneedle patch in order to 
increase the coating surface area. CLIP offers the unique ability to rapidly fabricate microneedles 
with a variety of geometries, including different needle heights, densities, and shapes, all of 
which impact coating surface area. The effects of altering these microneedle design parameters 
on coated cargo loading and delivery efficacy could be investigated in order to design the 
optimal microneedle patch for the delivery of coated therapeutics.  
4.4 Conclusions 
Here, we have demonstrated the ability to coat CLIP microneedles with protein cargo 
through a dip coating process using CLIP-fabricated microneedle coating mask devices, which 
ensure controlled spatial deposition of coating on the needles. The height of coating and cargo 
loading on the microneedle patches were shown to be controlled by altering the design of the 
coating mask device used to coat the patch, allowing for rapid, on-demand preparation of 
precisely coated microneedles. Coated microneedles were found to rapidly release their coated 
cargo both in solution and in porcine skin, with successful microneedle penetration observed in 
the porcine skin. The model enzyme lysozyme was found to retain its enzymatic activity 
throughout the microneedle coating process, demonstrating compatibility of the coating solution 
and coating method with protein cargo. The model protein BSA permeated full thickness porcine 
skin after application with coated microneedles, with distribution of the BSA within the skin 
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observed following microneedle application. Insulin and the model antigen OVA were 
successfully coated on CLIP microneedles, suggesting these microneedles show promise for 
delivering protein therapeutics. Future work will investigate the impact of microneedle geometry 
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
5.1 Summary 
 Microneedles are a promising tool for delivering therapeutics within and through the skin 
in a minimally-invasive manner. However, current microneedle manufacturing techniques are 
limited in their ability to fabricate microneedles rapidly, in a scalable manner, and with a high 
degree of control over microneedle design parameters. In this work, we utilized two novel 
microneedle fabrication platforms, the soft lithography technique PRINT and the additive 
manufacturing technique CLIP, to fabricate microneedles and investigated the utility of these 
microneedles for drug delivery applications.  
5.1.1 Cargo Delivery with Dissolvable PRINT Microneedles 
Using PRINT, we demonstrated the ability to fabricate dissolvable poly(vinyl 
pyrrolidone) (PVP) microneedles loaded with cargoes, including a small molecule dye, proteins, 
and nanoparticles, of a range of sizes and charges. The mild processing conditions used for the 
fabrication of PRINT microneedles ensured encapsulated protein cargo was able to maintain 
stability throughout the fabrication process. PRINT microneedles were shown to enhance the rate 
and extent of permeation of a small molecule drug surrogate through murine skin ex vivo 
compared to passive diffusion of the same cargo when applied topically. The permeation kinetics 
of microneedle protein cargo through murine skin ex vivo were found to depend on the molecular 
weight of the protein, with smaller proteins permeating more extensively while larger proteins 
showed limited permeation. Nanoparticles of a range of surface charges and functionalities were
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successfully deposited within murine skin following application with microneedles, with limited 
permeation through the skin.  
5.1.2 Encapsulated Cargo Delivery with CLIP Microneedles 
 For encapsulated drug delivery applications, CLIP microneedles were fabricated from 
drug-releasing materials: poly(ethylene glycol) (PEG), poly(caprolactone) (PCL), and 
poly(acrylic acid) (PAA). Microneedles of these materials are expected to release encapsulated 
cargo through swelling, degradation, and dissolution, respectively. Microneedles composed of 
two molecular weights of PEG (350 g/mol and 550 g/mol), PCL, and PAA were loaded with the 
small molecule drug surrogate rhodamine to assess the effect of microneedle composition on 
release kinetics of encapsulated cargo. The PEG and PCL microneedles showed limited release 
over the course of 1 week in solution, while the PAA microneedles completely dissolved after 15 
minutes in solution, releasing all encapsulated cargo. Microneedles of each of these materials 
were able to successfully penetrate murine skin, and the dissolvable PAA microneedles were 
shown to release encapsulated rhodamine within skin. The PEG and PAA microneedle 
compositions were used to investigate protein encapsulation within CLIP microneedles. Model 
proteins were found to have limited solubility in the PEG pre-microneedle resin, which resulted 
in aggregation of the protein cargo within and on the surface of the PEG microneedles after 
fabrication. The model enzyme lysozyme was found to lose activity after release from PAA and 
PEG microneedles, and a protein stability screen using simulated CLIP microneedle fabrication 
conditions revealed that the cause of this activity loss was likely the free radical 
photopolymerization process used in the fabrication of CLIP microneedles. Physical protection 
of protein cargo with a nanozyme formulation during CLIP microneedle fabrication was 
investigated but was not found to improve protein stability during the fabrication process.  
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5.1.3 Coated CLIP Microneedles for Transdermal Drug Delivery 
 A method for coating CLIP microneedles with cargo post-fabrication was developed. 
Microneedle coating mask devices, which can be used to isolate coating to only the needles of 
microneedle patches in a spatially controlled manner, were designed and fabricated using CLIP. 
These coating mask devices were then used to coat CLIP microneedles with protein cargo 
through a dip coating process. Control over the area of coating on the needles and cargo loading 
on the microneedle patches through alteration of the coating mask device design was 
demonstrated. Microneedles were found to rapidly release coated protein cargo after 1 minute 
both in solution and in porcine skin. The model enzyme lysozyme was shown to retain activity 
throughout the CLIP microneedle coating process. Permeation of model protein cargo across full 
thickness porcine skin was observed after application with coated microneedles. CLIP 
microneedles were successfully coated with insulin and the model antigen ovalbumin (OVA), 
paving the way for the development of coated CLIP microneedles for vaccine and therapeutic 
delivery applications.  
5.2 Future Directions 
5.2.1 Optimizing Cargo Delivery with PRINT Microneedles 
 Polymeric microneedles composed of biocompatible materials that dissolve or degrade in 
the skin are promising for transdermal drug delivery applications due to their lack of 
biohazardous sharps waste production, simple application process, and ability to control release 
of encapsulated cargo.1–4 Using PRINT, dissolvable microneedles composed of the 
biocompatible, water-soluble polymer PVP were fabricated. The amphiphilic nature of PVP 
allowed for the encapsulation of a range of cargoes, including both hydrophilic and lipophilic 
small molecules, proteins, and nanoparticles, and cargo stability was maintained during the 
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microneedle fabrication process. Moving forward, PRINT microneedles could be used to 
encapsulate other cargoes, including vaccine antigens, therapeutic proteins such as insulin, and 
drug-releasing nanoparticles for sustained therapeutic release in the skin.  
PRINT microneedles successfully delivered small molecule, protein, and nanoparticle 
cargo to murine skin ex vivo, with permeation across the full thickness skin observed for the 
small molecule and smaller protein cargo. Murine skin was utilized in these Franz diffusion cell 
permeation studies due to its availability and potential for translation into in vivo studies using 
nude mice. Skin from hairless mice has been commonly used as a membrane for transdermal 
permeation studies, but key differences exist between human skin and murine skin.5,6 Murine 
skin is 400 µm thick on average, while human skin can be anywhere from 600-3000 µm thick 
depending on location on the body.4,7,8 While studying the permeation of microneedle cargo 
across murine skin can be useful for predicting how the cargo might behave in vivo in the same 
species, the extent of permeation of compounds across murine skin is generally higher than with 
human skin.5–7,9 For a more accurate prediction of permeation across human skin, porcine skin, 
which has the most similar thickness, composition, and permeation rates to human skin, could be 
used as a membrane for Franz diffusion testing.6,8,10,11 
In this work, the permeation of microneedle cargo across skin was assessed for 24 hours, 
which is the maximum recommended length of Franz diffusion experiments before the skin 
membrane begins to significantly deteriorate.8 Translation of these microneedles to in vivo 
studies using nude mice would allow for assessment of permeation kinetics at longer time points, 
which could be particularly interesting for the large protein and nanoparticle cargoes that had 
limited permeation in 24 hours. The pharmacokinetics and biodistribution of the microneedle 
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cargo could be assessed at time points informed by the Franz diffusion permeation profiles of 
each cargo.  
PRINT microneedles are currently fabricated from the same microneedle master, which 
produces square pyramidal microneedles approximately 360 µm tall with a 200 µm base width. 
Microneedles of this geometry were found to enhance the permeation of small cargo through 
murine skin, but an alternative microneedle geometry might be necessary to achieve transdermal 
permeation and potentially systemic distribution of larger cargoes such as the 338 kDa 
butyrylcholinesterase (BuChE) protein. When delivered using the current PRINT microneedles, 
BuChE had little diffusion away from sites of microneedle penetration, likely due to its large 
size. If the cargo was deposited deeper in the skin by using longer microneedles, it would have to 
diffuse a smaller distance to reach the dermal blood supply and systemic circulation.4 Longer 
microneedles have been shown to more effectively enhance the permeation of therapeutic cargo 
than shorter microneedles.12–15 For example, Donnelly et al. showed that dissolvable polymer 
microneedles composed of poly(methylvinylether-co-maleic anhydride) with a height of 900 µm 
were able to significantly increase the extent of permeation of the small molecule drug 
theophylline compared to 350 µm tall microneedles of the same composition.13 Fabrication of 
longer PRINT microneedles would necessitate making new microneedle masters with the desired 
microneedle geometry, which could be achieved through techniques such as multidirectional UV 
lithography or laser ablation.13,16–19  
5.2.2 Encapsulated Cargo Delivery with CLIP Microneedles 
 Drug-releasing materials, including PEG, PCL, and PAA were successfully used to 
manufacture CLIP microneedles for drug delivery applications. A small molecule drug surrogate, 
rhodamine, was loaded into and released from microneedles of each of these materials. Complete 
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release of loaded rhodamine was observed from the dissolvable PAA microneedles after 15 
minutes in solution, but rhodamine release from the PEG and PCL microneedles was slow and 
limited, especially in the case of PCL and the more densely crosslinked PEG 350 microneedles, 
which released less than 1 % of loaded rhodamine over the course of 1 week in solution. If 
complete cargo release was even achievable from microneedles of these slow-releasing 
compositions, it would likely take months to years. Release this slow is not clinically relevant for 
the vast majority of microneedle applications, which necessitate therapeutic levels of cargo 
release within hours to days.4 Alternative microneedle materials with faster release rates, such as 
PLGA, could be explored for the fabrication of drug-releasing CLIP microneedles.20 Decreasing 
the crosslink density of the PEG microneedles, either by increasing the molecular weight of the 
PEG or by incorporating monofunctional oligomers into the pre-microneedle resin, could 
increase cargo release rates, but this would likely decrease the mechanical strength of the needles 
and could reduce their ability to penetrate skin.   
 Microneedles are particularly promising for the delivery of therapeutics that cannot be 
delivered orally, such as biologics. However, protein and nucleic acid therapeutics are fragile and 
susceptible to damage during free radical photopolymerization like that used in CLIP.21–23 Free 
radicals generated during photopolymerization can react with biologics, leading to fragmentation 
of DNA, denaturation or aggregation of proteins, and conjugation of polymers to proteins.21 A 
number of amino acid residues, particularly those containing amine and thiol groups, can react 
with free radicals and conjugate to (meth)acrylate groups on growing polymer chains.21,22,24 
Protein structural alteration either by free radical damage or polymer conjugation can lead to 
reduced therapeutic activity or immunogenicity.21,23 Immunogenicity is of particular concern for 
biologics delivered to the skin using microneedles, as the skin is a potent immune organ.1 Even if 
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activity of a protein is not lost during free radical photopolymerization, the protein can still 
conjugate to polymers and become trapped within the photopolymerized matrix, leading to 
incomplete release and reduced bioavailability.21 
 Physical protection of fragile biologic cargo has been utilized as a strategy for 
maintaining structure and activity during free radical photopolymerization. One method of 
physically protecting protein cargo during CLIP microneedle fabrication by formulating the 
protein into a nanozyme was explored in this work but was not found to retain protein activity 
after release from microneedles. Alternative physical protection strategies that have led to 
retained protein activity in other photopolymerized systems could be explored. Formulation of 
proteins into granules of lactose and gelatin and granulates of cyclodextrin and gelatin were 
found to retain protein function after release from PEG dimethacrylate and polyanhydride 
matrices, respectively.25,26 However, the protein loading in these granules was very low at less 
than 1 wt%.25,26 We are unable to fabricate microneedles with cargo loadings of greater than 5 
wt% using CLIP, which would severely limit the amount of protein that could be delivered. 
Another strategy used to preserve the structural stability of bovine serum albumin (BSA) during 
free radical photopolymerization is to formulate the protein with the chelator iminodiacetic acid 
(IDA) and copper ions.27 The IDA-copper ion complex is hypothesized to interact with the N-
terminus of BSA, which is a potential site of free radical attack for the protein.27 BSA formulated 
with IDA and copper ions was found to retain its stability after release from a photopolymerized 
PEG hydrogel.27 However, this strategy is only useful for proteins that have an affinity for IDA, 




5.2.3 Coated CLIP Microneedles for Transdermal Drug Delivery 
 CLIP microneedles were successfully coated with several protein cargoes, including 
BSA, lysozyme, OVA, and insulin. Lysozyme was found to retain activity throughout the 
microneedle coating process, and coated BSA was successfully delivered through porcine skin ex 
vivo using CLIP microneedles. This retention of activity and successful transdermal permeation 
of model proteins is promising, but the stability and permeation of each individual protein cargo 
must be assessed. Further characterization of the structural stability of OVA and insulin is 
needed. If these proteins retain stability during microneedle coating and are able to be delivered 
to skin ex vivo, microneedles coated with OVA and insulin could be translated in vivo for 
efficacy studies in mice to assess immune response and ability to lower blood glucose levels, 
respectively.  
The major limitation associated with using coated microneedles to deliver a therapeutic is 
limited cargo loading, which is dictated by the needle surface area available for coating. Low 
solubility of a therapeutic can further limit the potential cargo loading. Increasing the needle 
density would allow for more cargo to be coated on the microneedles while maintaining the 
patch size. Using CLIP to fabricate microneedles provides the unique opportunity to rapidly alter 
microneedle patch design to explore the effect of geometry on coated cargo loading. Examples of 
CLIP microneedles with microneedle densities of 64, 100, and 196 needles per cm2 patch area 





Figure 5.1 CLIP Microneedle Density. Images of PEG CLIP microneedles with (A) 196, (B) 
100, and (C) 64 needles per 1cm2 patch area. Scale bars measure 1 mm.  
 
One concern with increasing the needle density on a microneedle is the “bed of nails” 
effect, where a greater force is required to penetrate skin when the needle density is 
increased.28,29 An alternative approach to increasing cargo loading on coated microneedles is to 
design the microneedles to contain pockets or grooves in which larger amounts of coating can be 
contained (Figure 5.2).30–33 Han et al. demonstrated that grooved poly(L-lactic acid) (PLLA) 
microneedles fabricated using inclined UV lithography and hot embossing had a higher drug 
loading capacity for coated OVA and induced a higher immune response in vivo than smooth 
microneedles of the same dimensions.33 Using CLIP, microneedles with pockets or grooves of 







Figure 5.2 Pocketed and Grooved Microneedles. (A) Stainless steel microneedles with a 
pocket for coated cargo delivery. (B) Grooved PLLA microneedles for coated vaccine delivery. 
Images reproduced with permission from references 31 and 33, respectively.  
 
 Microneedle geometry parameters, including needle length,13,14 density,12,28,34 tip 
radius,35–37 and aspect ratio,35,38,39 have been shown to affect the insertion of needles into skin. 
However, comparatively little work has been done to investigate the impact of microneedle 
geometry on the transdermal permeation of cargo. Longer microneedles and lower microneedle 
densities have been shown to better enhance the permeation of cargo across skin when 
administered using solid or drug-encapsulating microneedles, but the effect of microneedle 
geometry on the permeation of coated cargo has not been extensively investigated.12,15 Different 
microneedle geometries might also be necessary for specific therapeutic applications. For 
example, shorter needles could more effectively target the antigen-presenting cells of the 
epidermis in the case of vaccine delivery, while longer needles might better target the dermal 
capillaries, enhancing uptake into circulation for systemic therapeutics.4,40–42 With CLIP, we 
have the opportunity to manufacture microneedles with almost unlimited control over geometry, 
which would allow for systematic investigations into the effect of microneedle design parameters 
on the transdermal permeation of coated cargo. Using this knowledge, we could design the 
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